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List of abbreviations                                     
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lncRNAs   Long noncoding RNAs 
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mRNA   Messenger RNA 
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siRNA    Small Interfering RNA 
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This thesis sheds light on the identification and functional role of microRNAs 
(miRNAs) in neuroblastoma chemoresistance. Neuroblastoma is an embryonal malignancy of 
childhood and the biology of neuroblastoma tumors is complex and dramatically heterogeneous 
(Brodeur, 2003). Most of the children diagnosed above one year of age, shows metastatic 
disease and poor prognosis (Brodeur, 2003). Chemotherapy is one of the principle mode of 
treatment for the metastatic disease.  However, resistance to drug represents the major clinical 
obstacle for the effective treatment of cancer. MiRNAs are small, endogenous, non-coding 
RNAs that reduce the translation of target mRNAs (Croce and Calin, 2005). Recently, miRNAs 
have been shown to modulate drug resistance in multiple cancers. However, the role of miRNAs 
in neuroblastoma chemoresistance is limited and poorly understood. In this study, we set out to 
identify miRNAs (and their networks/pathways) along with their functional targets involved in 
mediating drug resistance in neuroblastoma. 
In paper I, we performed miRNA profiling studies, by employing next generation deep 
sequencing technique to identify 34-downregulated and 8-upregulated miRNAs differentially 
expressed in neuroblastoma cell lines isolated from six patients at diagnosis (before therapy) 
and from the same patients at relapse (after therapy). Interestingly, 22 of the 34-downregulated 
miRNAs were located on chromosome 14q32 locus. MiRNAs from this locus are previously 
reported to be downregulated in multiple human cancers (Zehavi et al., 2012). Moreover, we 
also demonstrated that reduced expression of certain chromosome 14q32 miRNAs correlates 
with poor clinical outcome in a cohort consisting of 226-primary neuroblastomas. Furthermore, 
Ingenuity pathway analysis (IPA) of differentially expressed miRNAs revealed important 
biological pathways associated with the cancer progression and drug resistance. Hence, in this 
study, we identified a unique set of miRNAs which may be involved in the development of drug 
resistance in neuroblastoma.  
In paper II and III, we have investigated the previously unknown functional role of 
chromosome 14q32 located miRNAs (identified in Paper I), miR-376c-3p and miR-323a-3p 
which are downregulated in resistant neuroblastoma cell lines. Using a set of molecular 
methods, like flow cytometry, reverse transcriptase-polymerase chain reaction (RT-qPCR), 
western blot and luciferase reporter assay we confirm and validate CCND1 as a direct target of 
miR-376c-3p and STAT3 as a direct target of miR-323a-3p in neuroblastoma.  We show that, 
miR-376c-3p targets CCND1 and induce G1-cell cycle arrest whereas miR-323a-3p targets 
STAT3 and induce G1-cell cycle arrest and apoptosis in neuroblastoma cells. 
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Origin and development  
Neuroblastoma is an embryonal malignancy, which arises from the sympathoadrenal 
lineage of neural crest cells during development. Neural crest cells are the transient, migratory 
population of cells found in the embryo during development of the neural tube. These cells 
migrate and differentiates into diverse cell types including, peripheral neurons, enteric neurons, 
glia, melanocytes, cartilage, schwann cells, cells of the craniofacial skeleton and adrenal 
medulla (Knecht and Bronner-Fraser, 2002, Cheung and Dyer, 2013). The induction of neural 
crest cells and subsequent specification of the neural crest-derived cells is dependent upon the 
co-operative intrinsic and extrinsic functions of the regulatory gene network (Tsubota and 
Kadomatsu, 2018). 
Since neuroblastoma arises from the developing tissues, it generally occurs in infants 
and young children and the median age of diagnosis is 17 months (Maris, 2010). In addition, 
most of the children diagnosed above one year of age, shows metastatic disease and poor 
prognosis (Brodeur, 2003). The incidence of neuroblastoma is 10.2 per million children under 
15 years of age and it is necessary to improve outcome because 15% of all pediatric cancer 
related deaths are due to neuroblastoma (Maris, 2010, Cheung and Dyer, 2013) 
The biology of neuroblastoma tumors is complex and dramatically heterogeneous 
(Brodeur, 2003). The tumors may contain different types of neuroblastoma cells, which include 
cells resembling immature sympathetic neurons (N-type cells), non-neuronal schwann cell-like 
(S-type cells) and stem-like cells (I-type) cells. Patients with S-type Schwann cells have better 
outcome (Ratner et al., 2016). 
Biology and genomics  
Amplification of the MYC-family proto-oncogene, v-Myc Avian Myelocytomatosis 
Viral Oncogene Neuroblastoma Derived Homolog (MYCN) is one of the most common genetic 
abnormalities in neuroblastoma. MYCN amplification is found in approximately 25% of cases 
and it is highly correlated with advanced stage of disease and poor prognosis (Brodeur et al., 
1984, Huang and Weiss, 2013). The MYCN gene was originally discovered as amplified DNA 
sequences in the form of double minute chromosomes (DMs) and homogeneously staining 
regions (HSRs) in cells of neuroblastoma (Schwab et al., 1983, Kohl et al., 1983). 
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Because of the MYCN amplification, high levels of N-myc protein is generated; this 
protein is shown to act as a transcriptional regulator of certain genes involved in proliferation 
and differentiation processes, thus leading to tumorigenesis (Negroni et al., 1991, Wenzel et al., 
1991, Wenzel and Schwab, 1995). In addition, MYCN has been shown to regulate oncogenic 
miRNAs in neuroblastoma (Schulte et al., 2008). Moreover, MYCN is also shown to sensitize 
the neuroblastoma cells for drug-induced apoptosis (Fulda et al., 1999). MYCN is therefore 
considered a promising target for therapeutic intervention. Although direct targeting of MYCN 
is not yet achieved, alternative indirect approaches of MYCN targeting will most certainly gain 
success in future (Chen et al., 2018b).  
Chromosomal gains and losses are the means of frequently occurring genetic variations 
in human neuroblastoma. Caron and colleagues studied the allelic loss of certain chromosomes 
in 89-neuroblastomas and they found that loss of chromosome 1p is a strong prognostic factor 
in patients with neuroblastoma, independently of age and stage (Caron et al., 1996). Similarly, 
chromosome 11q is also frequently deleted in neuroblastoma and that unbalanced 11q and 1p36 
loss of heterozygosity (LOH) are independently associated with a worse outcome in patients 
with neuroblastoma (Attiyeh et al., 2005). In contrast to deletions, gain of 17q is one of the 
most frequent cytogenetic abnormalities in neuroblastoma cells. The 17q gain serves as an 
important prognostic factor with negative outcome in children with neuroblastoma (Bown et 
al., 1999). Additionally, gains of 1q, 2p, 7q, 11p and losses of 3p, 4p, 9p and 14q have also 
been documented in neuroblastoma (Cheung and Dyer, 2013). 
Mutations are observed in certain genes in neuroblastoma. Mutations in the paired like 
homeobox 2b (PHOX2B) which is the regulator of normal autonomic nervous system 
development was the first predisposing gene identified and linked to hereditary neuroblastoma 
(Trochet et al., 2004). In addition, heritable mutations in the anaplastic lymphoma kinase (ALK) 
gene, which encodes a receptor tyrosine kinase, lead to its constitutive activation and in vivo 
tumor formation in mouse models (George et al., 2008, Janoueix-Lerosey et al., 2008, Mosse 
et al., 2008, Chen et al., 2008). Moreover, somatic mutations were also observed in alpha 
thalassemia/mental retardation syndrome X-linked (ATRX) gene in a cohort of 104 patients with 
advanced stage neuroblastoma (Cheung et al., 2012). Albeit with low frequencies, mutations 
have also been identified in protein tyrosine phosphatase-non receptor type 11 (PTPN11), 
neuroblastoma RAS viral oncogene homolog (NRAS) and MYCN (Pugh et al., 2013). 
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Clinical aspects  
Neuroblastoma may arise anywhere along the parasympathetic nervous system in the 
neck, chest, abdomen or pelvis. However, tumors are mostly found in the adrenal medulla or 
paraspinal ganglia (Maris, 2010) (Figure 1). The presence of tumor cells in the bone marrow or 
tissue biopsies and the higher levels of urine catecholamines can be used to diagnose 
neuroblastomas (Maris et al., 2007). 
 
Figure 1. Clinical presentations in neuroblastoma. The primary distribution of neuroblastoma in children is mostly 
in the neck, chest, abdomen and pelvis. Tumors are mainly observed in paraspnial nerve tissue and adrenal glands. 
Illustration available from: https://ghr.nlm.nih.gov/condition/neuroblastoma with permission from the National 
Cancer Institute © (2014) Terese Winslow LLC, U.S. Govt. 
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Staging of cancer helps to plan treatment and predict patient’s outcome. In 1988, an 
internationally accepted staging system based on clinical, radiographic and surgical evaluation 
was developed called International Neuroblastoma Staging System (INSS). However, 
modifications of INSS were proposed later for the incorporation of both clinical and biological 
features in the prediction of prognosis (Brodeur et al., 1993, Brodeur et al., 1988). Therefore, 
in 2009, a new pre-treatment risk-stratification classification system called International 
Neuroblastoma Risk Group (INRG) was established using 13 prognostic factors in a cohort of 
8,800 children diagnosed with neuroblastoma to facilitate the comparison of risk based clinical 
trials conducted in different parts of the world. The INRG task force later proposed a new 
staging system based on clinical criteria and image-defined risk factors (IDRFs) called 
International Neuroblastoma Risk Group Staging System (INRGSS) (Monclair et al., 2009, 
Cohn et al., 2009). The currently followed INRG classification system broadly categorize 
neuroblastoma tumors into four risk groups (very low risk, low risk, intermediate risk and high 
risk) based on the analysis of age at diagnosis, INRG tumor stage, histologic category, grade of 
tumor differentiation, DNA ploidy, MYCN oncogene status and chromosome 11q status (Maris, 
2010). 
Due to the clinical and biological heterogeneity of neuroblastoma tumors, the treatment 
approaches are mainly based on INRG risk group system. Treatment of low and intermediate 
risk patients rely on surgery with or without chemotherapy. However, subsets of infants with 
localized tumors are cured with observation alone, without any cytotoxic treatment. Patients of 
low and intermediate risk group show excellent prognosis as opposed to high-risk patients. 
Treatment of high-risk neuroblastoma patients is mainly categorized into three phases: 
Induction of remission phase (multiple rounds of chemotherapy and surgery), consolidation of 
remission phase (high-dose chemotherapy with autologous stem-cell rescue and external-beam 
radiotherapy) and the post-consolidation phase (where efforts are made to treat the therapy 
resistant minimal residue disease by immunotherapy regimens, cytokines and isotretinoin) 
(Pinto et al., 2015). Despite the multimodal treatment regimens, 50 to 60% of patients with 
high-risk neuroblastoma will ultimately relapse with no curative treatment available for these 
patients. The treatment failure has been associated with acquired drug resistance or the selection 
of rare resistant clones from a heterogeneous tumor environment or both (Maris, 2010). 
Therefore, recent research is focused around developing biological based therapies which 
specifically target important genes, proteins or oncogenic pathways responsible for malignant 
transformation and progression in neuroblastoma (Brodeur, 2003). 
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Drug resistance in human cancer 
Mechanisms of drug resistance 
Although there are significant advances in the cancer treatment approaches, no approach 
is yet 100% effective against this deadly disease (Gottesman, 2002). Chemotherapy is one of 
the principle mode of treatment for cancer.  However, resistance to drug represents the major 
clinical obstacle for effective treatment of cancer.  Drug resistance accounts for 90% of 
treatment failure in cancer patients (Longley and Johnston, 2005).  The resistance can be 
developed against every effective anticancer drugs and resistance to anticancer treatment can 
be multifactorial. Owing to this complexity, resistance mechanisms are broadly categorized into 
intrinsic and extrinsic mechanisms. Whereas intrinsic resistance mechanisms are inherent or 
pre-existing in the tumor cells, the extrinsic or acquired resistance mechanisms are developed 
during the course of treatment. Acquired resistance can be due to mutations or adaptive 
responses which increases the expression of the therapeutic targets, the activation of alternative 
compensatory signaling pathway not targeted by the treatment, selection of the resistant clones 
from the subpopulation of tumor cells among others (Holohan et al., 2013, Buhagiar and Ayers, 
2015, Kartal-Yandim et al., 2016).  
 A range of molecular mechanisms have been observed which lead to drug resistance 
including alterations in drug transport and drug metabolism, alterations in drug targets, DNA-
damage repair mechanisms, downstream resistance mechanisms like dysfunctional apoptosis 
and autophagy, local tumor microenvironment, cancer stem cells and adaptive off-target 
responses (Figure 2) (Holohan et al., 2013, Kartal-Yandim et al., 2016). All these drug 
resistance mechanisms can act independently or in combination leading to multidrug resistance 
(MDR).  MDR is a resistance mechanism in which malignant cells become resistant to 
structurally and functionally unrelated chemotherapeutic agents (Gillet and Gottesman, 2010).  
Drug transport: Influx and efflux 
In order for the drug to exert its effect on the tumor cells, it must be efficiently 
distributed along the body and reach the tumorous cells. However, pharmacokinetic effects such 
as absorption, distribution, metabolism and elimination are important factors, which can limit 
the amount of drug reaching the tumor cells (Holohan et al., 2013). After the drug reaches the 
tumor cells, it must be transported into the cells in sufficient dosage to exert its effect. The drug 
can enter the cells mainly through three different routes.  Drug can get into cells through i) 
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passive diffusion across the plasma membrane (e.g. vinblastine, doxorubicin), ii) by energy 
dependent transport  
Figure 2. The drug resistance mechanisms in cancer cell. Resistance to drug can be acquired through various 
mechanisms including alterations in DNA damage repair processes, alterations in drug targets, decreased drug 
influx and increased drug efflux, resisting drug-induced apoptosis, drug compartmentalization and drug 
metabolism. 
through transmembrane transporter proteins (e.g. nucleoside analogs) and iii) by endocytosis 
(e.g. immunotoxins) (Gottesman, 2002). The influx of drug into the cells is often altered leading 
to decreased drug uptake. Therefore, drug accumulation deficiencies is one of the major cause 
of drug resistance in cancer. The solute carrier (SLC) transporter superfamily is primarily 
involved in uptake of small molecules into cells including chemotherapeutic drugs. Mutations 
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and/or reduced expression have been observed in the SLC family transporter proteins, limiting 
the entry of drugs and causing cells resistant to drugs (Gillet and Gottesman, 2010). For 
example, reduced expression of SLC22A4 was reported in a cohort of 251 primary 
neuroblastomas (Fletcher J.I., 2012).    
Contrary to influx, cell membrane transporter proteins also mediate removal or efflux 
of drugs from the cells. Three efflux pumps have been extensively studied namely ABCB1, 
ABCC1 and ABCG2. These transporter proteins belong to a large family of ATP-dependent 
transporters known as ATP binding cassette (ABC) family (Higgins, 1992). ABC family 
members are involved in transport of multiple structurally and mechanistically unrelated 
chemotherapeutic agents like the removal of taxanes, topoisomerase inhibitors and 
antimetabolites like 5-fluorouracil, methotrexate and pemetrexed. They are widely expressed 
in tissues and human cancers and are not only involve in transport of drugs but also in the 
transport of nutrients and necessary biological molecules across plasma and intracellular 
membranes (Goldstein et al., 1989, Gottesman, 2002).  
The multidrug transporter energy-dependent drug efflux pump ABCB1 (also called P-
gp or MDR1) is a product of the MDR1 gene (Chen et al., 1986). The MDR1 transporter was 
the first ABC transporter identified. It is involved in transport of a large variety of hydrophobic 
anticancer drugs like doxorubicin, etoposide, irinotecan, daunorubicin, vinblastine, vincristine 
and taxol (Fletcher J.I., 2012, Gottesman, 2002). MDR1 is over-expressed in many tumors thus 
causing intrinsic drug resistance. MDR1 is also shown induced by chemotherapy thus resulting 
in acquired drug resistance (Thomas and Coley, 2003). Therefore, the obvious therapeutic 
strategy would be to develop MDR1 inhibitors but the results from clinical trials for MDR1 
inhibitors (e.g. Tariquidar in advanced breast carcinoma) are unsuccessful (Pusztai et al., 2005). 
In neuroblastoma, MDR1 was shown highly expressed in drug resistant cell lines and in post-
treatment samples from relapsed patients, however, results from these studies were equivocal 
due to small sample size and had no prognostic significance (Goldstein et al., 1990, Flahaut et 
al., 2009).  
Another ABC family transporter, ABCC1 (also called multidrug resistance associated 
protein1; MRP1) transports negatively charged anticancer drugs and neutral drugs that have 
been modified by conjugation with acidic ligands such as, sulfate, glutathione (GSH), and 
glucuronate (Borst et al., 2000). This member is also widely expressed across tissues and human 
cancers and have a broad spectrum of anticancer drug transport activity. MRP1 over-expression 
is associated with drug resistance and treatment failure across cancer types (Zalcberg et al., 
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2000, Triller et al., 2006). In neuroblastoma, MRP1 has been shown to efflux etoposide, 
vincristine, doxorubicin and irinotecan. Interestingly, high expression of MRP1 is associated 
with poor clinical outcome in primary neuroblastomas (Fletcher J.I., 2012, Haber et al., 2006, 
Oberthuer et al., 2006). In addition, Manohar and colleagues demonstrated that MRP1 is a direct 
transcriptional target of N-myc and it is highly expressed in MYCN-amplified neuroblastoma 
(Manohar et al., 2004). Moreover, an inhibitor of MRP1, reversan was shown to mediate drug 
resistance in a mouse model of neuroblastoma (Burkhart et al., 2009).  
The ABCG2 transporter (also called breast cancer resistance protein; BCRP) has a 
narrow range of drugs as compared to MDR1 and MRP1. BCRP is capable of transporting 
doxorubicin, topotecan, mitoxantrone, methotrezate and it is over-expressed in multiple drug 
resistant tumors (Alisi et al., 2013). Other members of ABC family are also involved in drug 
transport in human cancer but they are not well studied.  
Drug sequestration is another major factor in facilitating multidrug resistance in cancer 
by limiting the amount of drug having access to intracellular targets. Whereas most commonly 
used anticancer drugs have their targets located in the nucleus such as DNA or topoisomerases, 
many new drugs have targets in the intracellular compartments like mitochondria, endosomes, 
lysosomes, golgi apparatus and endoplasmic reticulum (ER). Therefore, the ability of anticancer 
drugs to effectively concentrate in these cellular compartments will determine the drug’s 
therapeutic efficiency. However, multiple resistance mechanisms can lead to altered 
intracellular distribution of drugs resulting in drug resistance (Duvvuri and Krise, 2005). 
Drug metabolism: activation and inactivation 
After the drug enters the body, it is absorbed and systemically distributed throughout 
the body. Most drugs undergo chemical transformation in the body. There are many 
biochemical factors involved in metabolism and pharmacological activity of drugs. Drugs are 
transformed in the body by a variety of drug metabolism enzymes (DMEs) to yield 
pharmacologically active or inactive metabolites (Axelrod, 1960). DMEs are thus the second 
line of cellular resistance. Different mechanisms exist for each different class of drugs as 
reviewed in  detail by Sheweita SA (Sheweita, 2000).  
Alterations in drug targets 
Alterations in drug or its targets have profound effect on the anti-cancer treatment 
therapy. The genomic instability persistent in cancer cells can cause mutations or aberrant 
expression of drug targets. The under or over-expression of drug targets could thus result in 
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loss of therapeutic potential, leading to drug resistance (Kartal-Yandim et al., 2016). For 
example, topoisomerase inhibitors (e.g. anthracyclins) are widely used in anticancer treatment 
and are highly dependent on the target for its effect. However, reduced drug target expression 
reduces the effectiveness of inhibitors thus conferring resistance to the anticancer drugs (Beck 
et al., 1999). In another example, germline and somatic activating mutations were identified in 
ALK in neuroblastoma. These mutations led to autophosphorylation and constitutive activation 
of the receptor tyrosine kinase (RTK). Inhibition of ALK by crizotinib or ceritinib (ALK 
inhibitors) showed poor response rate and acquired secondary mutations were observed in the 
ALK kinase domain of the treated patients (Wang et al., 2017a). Similarly, acquired resistance 
was observed against the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
(Gefinitib) in advanced non-small cell lung cancer (NSCLC) patient. The initially responsive 
patient ultimately suffered relapse after 2 years of complete remission. The development of 
secondary mutation was observed in the EGFR, which conferred resistance to gefitinib 
(Kobayashi et al., 2005).  
DNA damage repair mechanisms 
Most anticancer drugs (e.g. platinum drugs or alkylating agents) are designed to target 
actively dividing cells causing DNA damage and ultimately leading to cell cycle arrest and 
programmed cell death (apoptosis). Depending upon the type and extent of DNA damage, a 
complex of interacting pathways is activated which can detect the damage and activate a set of 
proteins that can induce either cell cycle arrest or apoptosis. The cell cycle arrest induced upon 
DNA damage allows cells to repair the damaged DNA (Bouwman and Jonkers, 2012, Gillet 
and Gottesman, 2009). In order to fix the damaged DNA, cells have developed multiple DNA 
repair processes including mismatch repair system (MMR), nucleotide excision repair (NER), 
base excision repair system (BER), homologous recombination (HR), inter-strand crosslink 
(ICL) repair and non-homologous end-joining (NHEJ). This ability of cells to repair the 
damaged DNA by a multitude of repair mechanisms can reduce the efficiency of anticancer 
drug treatments. But, mutations in the components involved in these DNA repair pathways can 
lead to deficiencies in DNA damage repair systems, which are mainly associated with drug 
resistance (Ciccia and Elledge, 2010, Bouwman and Jonkers, 2012). For example, the excision 
repair cross complementing 1 (ERCC1), an important component of NER machinery has been 
linked to drug resistance in gastric and non-small cell lung cancer (Lord et al., 2002, Kwon et 
al., 2007) and loss of human mutL homolog (hMLH1) expression, a MMR repair system 
component has been associated with drug resistance in ovarian cancer (Strathdee et al., 1999). 
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Therefore, alterations in DNA damage repair mechanisms will be crucial in determining the 
drug resistant phenotype in cancer cells. Importantly, the obvious therapeutic strategy will be 
to inhibit the DNA repair machinery in combination with increased cytotoxic therapy in cancer 
cells.   
Downstream resistance mechanisms in cancer  
The principle aim of any chemotherapeutic drug treatment is to induce cell death. 
However, several adaptive responses are initiated within cells, which help evade apoptosis and 
promote cancer cell survival. These adaptive responses include deregulation of apoptosis, 
activation of upstream pro-survival signaling pathways and stress induced autophagy (Holohan 
et al., 2013). 
The deregulation or dysfunction of apoptosis is one of the classic hallmarks of cancer 
(Hanahan and Weinberg, 2000) and therefore resistance of cell to induce apoptosis can cause 
resistance to cancer drug treatment. Apoptosis can be induced either by the mitochondrial 
pathway (also called intrinsic pathway) or by the activation of death receptors (extrinsic 
pathway). Both pathways ultimately lead to activation of specific proteases, the caspases. The 
caspases mediate the biochemical and morphological activities in the cell responsible for the 
DNA fragmentation and membrane blebbing, which are the characteristic features of apoptosis. 
The BCL-2 family of genes mainly regulate apoptosis mediated by the mitochondrial pathway. 
The anti-apoptotic BCL-2 family proteins (BCL-XL and MCL-1) and the pro-apoptotic family 
proteins (BAX, BAD, and BAK) are important mediators of therapy response. They can 
interplay to inhibit or facilitate cell death, which involves mitochondrial outer membrane 
permeabilization (Elmore, 2007). Therefore, amplification, translocation, mutations or other 
alterations in the BCL-2 family genes could ultimately lead to drug resistance.  
Autophagy (here, macroautophagy) is the evolutionary conserved catabolic process 
wherein targeted cytoplasmic components are sequestered and engulfed by double membrane 
vesicles (called autophagosome) which eventually fuses with lysosome (called autolysosome) 
for bulk degradation (Sui et al., 2013, Yang and Klionsky, 2010, Bhujabal, 2017).  Autophagy 
has a complex role in cellular biology in that it not only allows degradation of damaged 
organelles or excessive proteins, but also it is an adaptive response to metabolic stresses like 
nutrient deprivation, absence of growth factors, hypoxia, glucose deprivation, cytotoxic drugs, 
etc. Autophagy can be upregulated or downregulated in response to various signaling pathways 
and by chemotherapy. The induction of autophagy in response to chemotherapeutic drug 
treatment can have either pro-death or pro-survival role depending on the cell type. Autophagy 
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can be activated to protect cells from the anti-cancer drug induced metabolic or therapeutic 
stress thus allowing the resistant cells to survive, eventually promoting drug resistance. Here, 
autophagy can be therapeutically inhibited to re-sensitize the resistant tumor cells and enhance 
effectiveness of chemotherapeutic agents. Contrary to this, autophagy could also induce 
autophagic cell death which is physiologically different from type I programmed cell death or 
apoptosis. As mentioned earlier, dysfunctional apoptosis is a hallmark of cancer, thus 
autophagic cell death is an alternative death mechanism, which can be activated to circumvent 
drug resistance (Sui et al., 2013).  
Role of tumor microenvironment in drug resistance 
The malignant and non-transformed cells together create a tumor microenvironment 
(TME), which may consist of extra cellular matrix (ECM), fibroblasts, pericytes, adipocytes, 
immune cells, inflammatory cells and blood vessels. These TME cells communicate 
intracellularly by a complex network of integrin, cytokines, chemokines, and growth factors 
thus promoting the tumor growth and maturation (Balkwill et al., 2012). TME can thus protect 
malignant cells from the toxic effects of drugs thus allowing them to evade apoptosis and to 
develop cancer drug resistance (Holohan et al., 2013). For example, Challagundla and 
colleagues discovered a complicated molecular mechanism wherein miR-155 is exchanged 
between neuroblastoma tumors (via exosomes) and tumor associated macrophages (TAMs) 
present in the tumor microenvironment. MiR-155 targets telomeric repeat binding factor 1 
(TERF1), which functions as an inhibitor of telomerase. High telomerase activity is one of the 
hallmarks of cancer. Interestingly, the TERF1-proteins levels were low in the cancer cells 
resistant to chemotherapy (Challagundla et al., 2015). In another example, the growth factor 
interlukin-6 (IL-6) produced by bone-marrow derived mesenchymal stem cells (BMMSC) and 
TAMs in the bone-marrow microenvironment promotes the growth and survival of 
neuroblastoma cells. IL-6 mediated drug resistance by activating the signal transducer and 
activator of transcription 3 (STAT3), which is necessary for the upregulation of multiple survival 
factors including survivin and anti-apoptotic BCL-2 family members (Ara et al., 2009, Ara et 
al., 2013) 
Cancer stem cells and drug resistance 
Cancer stem cells (CSCs) are the rare immortal cells found within tumors that have stem 
cell like capacity to self-renew. They exhibit the characteristics of both stem cells and cancer 
cells and have the ability to produce tumors in transplanted host animals (Yu et al., 2012). In 
1994, Lapidot and colleagues first proposed the evidence of cancer stem cells. They identified 
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a population of cells from acute myeloid leukemia (AML) patients which, when transplanted, 
initiated AML in severe combined immune-deficient (SCID) mice (Lapidot et al., 1994). 
Subsequently, cancer stem cells were identified in various cancer types including breast, brain, 
colon, pancreas, lung, prostate, melanoma, glioblastoma (Yu et al., 2012) and neuroblastoma 
(Ross et al., 1995). 
CSCs are inherently drug resistant. They show high levels of drug efflux proteins, 
amplified checkpoint activation, DNA damage repair, increased Wnt/β-catenin and Notch 
signaling (Shervington and Lu, 2008, Eyler and Rich, 2008) and therefore they are one of the 
major factors in cancer relapse and poor patient outcome. In one study, it was demonstrated that 
a subpopulation of neuroblastoma cells termed ‘side population’ express higher levels of 
ABCG2 transporter in mouse neuroblastoma and are enriched for neuroblastoma stem cells 
(Stepanova, 2015). 
The CD133 cell surface marker expression is a characteristic of the stem cells. The 
treatment with variety of drugs have shown the enrichment of CD133 positive stem cells in vivo 
in different chemotherapy resistant cancers (Alisi et al., 2013). Vangipuram and colleagues 
demonstrated that CD133 positive neuroblastoma cells were more resistant to anticancer drugs 
than the CD133 negative cells (Vangipuram et al., 2010).   
Small RNAs in human cancer 
The ‘small RNAs’ are generally referred to as small non-coding RNA molecules which 
are less than 300 nucleotides in length (Hagemann-Jensen et al., 2018). There are different 
classes of small RNAs which includes transfer RNAs (tRNAs), small nuclear RNAs (snRNAs), 
small nucleolar RNAs (snoRNAs), miRNAs, PIWI-interacting RNAs (piRNAs), small 
interfering RNAs (siRNAs), transcription initiation RNAs (tiRNAs) and splice site RNAs 
(spliRNAs) (Morris and Mattick, 2014). These small RNAs participate in processes like RNA 
translation, RNA splicing, RNA modifications, mRNA destabilization or degradation, 
epigenetic processing, gene silencing, transcription initiation and splicing mechanisms 
(Hagemann-Jensen et al., 2018, Morris and Mattick, 2014). In short, they are involved in the 
regulation of the genome organization and gene expression. Therefore, the functional role of 
these small RNAs needs to be investigated further. In this thesis, we will discuss in details about 
the role of miRNAs in general and in relation to neuroblastoma. 
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MicroRNAs: Biogenesis and mode of action 
MiRNAs are a large family of short (~22-25 nucleotides), endogenous, non-coding 
RNAs, which binds the partial or perfect complementary sequences in the 3’-untranslated 
region (UTR) of target messenger RNAs (mRNAs) leading to translational repression or mRNA 
degradation (Croce and Calin, 2005). Mounting evidence have established the roles of miRNAs 
in regulation of important cellular processes like survival, proliferation, metastasis, 
development, apoptosis and stress response (Croce and Calin, 2005).  In 1993, the first miRNA 
was discovered while studying the development timing of the nematode Caenorhabditis 
elegans (Lee et al., 1993). Since then thousands of miRNAs have been identified across 
different species and the number is still increasing (Table 1).  
 Table 1: List of microRNA databases                                                                                  
 
The biogenesis of miRNAs takes place in a sequential manner which starts in the nucleus 
and ends in the cytoplasm (Figure 3). The miRNA-genes are mostly transcribed in the nucleus 
by RNA polymerase II (Pol II) enzyme into long primary miRNAs (pri-miRNAs) characterized 
by unique hairpin structure with 5’-cap and polyadenylated tail (Lee et al., 2004). The 
microprocessor complex (drosha ribonuclease III; DROSHA and its essential co-factor 
DiGeorge critical 8; DGCR8) further crops these pri-miRNAs into ~70-100 nucleotides long 
precursor miRNAs (pre-miRNAs) (Gregory et al., 2004, Denli et al., 2004). However, an 
alternative ‘splicing machinery’ has been reported for intronic miRNAs (called Mirtrons) which 
does not involve drosha-mediated cleavage (Ruby et al., 2007, Berezikov et al., 2007). Mirtrons 
have been discovered in several species including mammals, fruit-fly, Drosophila 
melanogaster and the nematode, Caenorhabditis elegans (Winter et al., 2009). After nuclear 
processing, the pre-miRNAs produced are then exported  to the cytoplasm by exportin-5 
(XPO5) in complex with GTP-binding nuclear protein, RAN (Ran-GTP) (Yi et al., 2003).  
Database Link Reference 
deepBase http://deepbase.sysu.edu.cn/ (Yang et al., 2010) 
miRGen2.0 http://www.microrna.gr/mirgen/ (Alexiou et al., 2010) 
miRNAMap http://miRNAMap.mbc.nctu.edu.tw/ (Hsu et al., 2006) 




Figure 3: The microRNA biogenesis pathway 
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In the cytoplasm, an RNase III enzyme-DICER1 along with transactivation-responsive RNA-
binding protein (TRBP) cleaves the pre-miRNA into an approximately 22 nucleotides long 
double-stranded (ds) miRNA with 2-nucleotide 3’ overhangs (Chendrimada et al., 2005). For 
some miRNAs, an additional endonuclease step by argonaute protein 2 (AGO2) cleaves the 
pre-miRNA generating the nicked Ago2-cleaved-precursor-miRNA (ac-pre-miRNA), which 
may facilitate the strand dissociation of mature miRNA (Diederichs and Haber, 2007). After 
DICER1 mediated cleavage, the ds miRNA is unwinded by helicases (like p68, p72, RNA 
helicase A, RCK/p54, TNRC6B, Gemin3/4 and Mov10) into single stranded mature miRNA 
(the guide strand) and the complementary passenger strand is subsequently degraded (Winter 
et al., 2009). The mature miRNA is then incorporated into the miRNA-induced silencing 
complex (miRISC) containing the argonaute proteins (AGO1, AGO2, AGO3 or AGO4) 
together with the members of GW182 family proteins and accessory factors. The mature 
miRNA-miRISC complex recognizes the complementary sequences in the 3’-UTRs of target 
mRNAs leading to mRNA degradation, destabilization or translational repression (Gregory et 
al., 2005, Winter et al., 2009). 
Studies have, however, shown that the mature miRNA can also bind the 5’-UTR or the 
open reading frame (ORF) of the mRNA (Lytle et al., 2007, Moretti et al., 2010). In addition, 
instead of its usual function of guiding argonaute protein complexes for target mRNA silencing, 
miRNAs have been shown to act independently of argonaute proteins by interacting directly 
with ribonuceloproteins (decoy activity) (Beitzinger and Meister, 2010). Moreover, miRNAs 
have also been shown to directly interact with DNA and regulate the gene expression at 
transcriptional level (Kim et al., 2008). 
Given the nature of miRNA and its interaction with target mRNA, it is not surprising 
that a single miRNA can target multiple genes. This regulatory function of miRNAs can thus 
affect many cellular pathways controlling important developmental and oncogenic processes. 
Scientists have developed various different bioinformatic tools to predict miRNA targets (Table 
2). Some of the predicted miRNA targets have been experimentally validated in various cancer 







Table 2: List of microRNA target prediction tools 
Tool Link Reference 
miRTarBase http://miRTarBase.mbc.nctu.edu.tw/ (Chou et al., 2018) 
miRDB http://mirdb.org (Wong and Wang, 2015) 
DIANA-microT http://www.microrna.gr/webServer (Paraskevopoulou et al., 2013) 
miRWalk http://mirwalk.uni-hd.de/ (Dweep et al., 2011) 
microRNA.org http://www.microrna.org (Betel et al., 2008) 
Targetscan http://www.targetscan.org (Lewis et al., 2005) 
 
MicroRNAs and their roles in human cancer 
In 2002, Calin and colleagues reported the first study identifying the involvement of 
miRNAs in cancer. They observed a frequent deletion and downregulation of chromosomal 
region 13q14 in B-cell chronic lymphocytic leukemia (CLL). This chromosomal region, which 
harbored miR-15 and miR-16 miRNA genes, was deleted or downregulated in about 68% of 
patients with CLL (Calin et al., 2002). The same group reported in 2004 that about 50% of 
miRNA genes are mapped to cancer-associated genomic regions or in fragile sites. They also 
demonstrated that the miRNAs located in the deleted regions have low levels of expression in 
many cancers (Calin et al., 2004). 
Numerous studies have demonstrated miRNAs acting as oncogenes and/or tumor 
suppressors and affecting the different hallmarks of cancer (Hanahan and Weinberg, 2000) like 
sustaining proliferative signaling (Si et al., 2007, Medina et al., 2010), activating invasion and 
metastasis (Gregory et al., 2008, Chen et al., 2011), inducing angiogenesis (Hua et al., 2006) 
and resisting cell death (Lima et al., 2011) (Figure 4). Thus, the deregulated expression of 
miRNAs can have significant impact on the normal functioning of the cellular processes leading 




Figure 4: MicroRNAs targeting hallmarks of cancer 
Dysregulation of miRNA expression is a common feature of cancer. MiRNAs are shown 
to be over-expressed or under-expressed, and this aberrant expression has been associated with 
cancer phenotype (Deng et al., 2008). Whole-genome miRNA expression profiling has been 
used to detect the global expression of miRNAs in tumor specimens relative to normal tissues 
(Lu et al., 2005). In addition, miRNA profiling not only distinguish between cancerous and 
normal tumors but also between parental and resistant tumors. For instance, in our study, we 
employed the next generation sequencing technique to identify differentially expressed 
miRNAs from six different parental and resistant neuroblastoma cell lines isolated before and 
after chemotherapy treatment. We observed a downregulated expression of several miRNAs in 
the resistant cell lines, which is in concordance with the earlier studies demonstrating a general 
downregulation of miRNAs in cancer (Roth et al., 2016, Williams et al., 2017) 
Several methods are developed for detecting miRNAs like bead-based miRNA 
profiling, miRNA microarrays, RT-qPCR, in situ hybridization techniques and the recent high-
throughput sequencing. Moreover, loss and gain-of-function studies have been established to 
study the biology of miRNAs by overexpressing or silencing of particular miRNAs with 
synthetic mimics or antagomirs, respectively (Iorio and Croce, 2012). Overall, these studies 




Due to their small size, miRNAs are more stable and resistant to degradation. In 
addition, extra-cellular miRNAs can be easily detected and extracted from body fluids such as 
blood (total blood, plasma or serum), exosomes, and even from urine, saliva and sputum (Weber 
et al., 2010). These so called circulating miRNAs are associated with various 
pathophysiological conditions and can thus be used as prognostic biomarkers for early 
diagnosis. For example, Lawrie et al. (2008), were the first to detect increased levels of tumor 
associated miRNAs (miR-155, miR-210 and miR-21) in serum of patients with diffuse large B-
cell lymphoma and that increased levels of these miRNAs correlated with improved relapse-
free survival (Lawrie et al., 2008). 
MiRNAs can also response to specific therapies. In cholangiocarcinoma cell lines, 
targeted inhibition of miR-21 and miR-200b led to increased sensitivity to gemcitabine. This 
was the first study demonstrating the involvement of miRNAs in modulating drug resistance in 
cancer cells (Meng et al., 2006).  
MicroRNAs as oncogenes and tumor suppressors 
As mentioned earlier, dysregulation of miRNAs can affect one or several cellular 
processes including survival, proliferation, invasion, migration, metastasis, differentiation and 
apoptosis by acting as oncogenes or tumor suppressor genes (Babashah and Soleimani, 2011). 
Cancer cells generally show the abundance of specific oncogenic miRNAs (also called 
oncomiRs) and the loss of tumor-suppressor miRNAs (Figure 5) (Table 3) (Esquela-Kerscher 
and Slack, 2006). 
The oncomiRs repress the tumor suppressor genes, and/or genes that control cell 
differentiation or apoptosis (Esquela-Kerscher and Slack, 2006, Lu et al., 2005, Babashah and 
Soleimani, 2011). For instance, miR-155 is over-expressed and acts as an oncomiR by targeting 
SH2 domain-containing inositol 5-phosphatase 1 (SHIP1) in acute myeloid leukemia (Xue et 
al., 2014). In breast cancer, miR-21 was highly over-expressed compared to matched normal 
breast tissues. Thus, knockdown of miR-21 by anti-miR-21 oligonucleotides, suppressed cell 
growth in vitro and tumor growth in xenograft mouse model probably by indirect regulation of 
BCL2 expression (Si et al., 2007). 
The tumor-suppressor miRNAs negatively regulate protein-coding oncogenes and or 
genes that inhibit cell differentiation or apoptosis (Esquela-Kerscher and Slack, 2006, Lu et al., 
2005, Babashah and Soleimani, 2011). For example, the tumor suppressor, miR-34a have been 
shown to target MYCN (Wei et al., 2008) and E2F transcription factor 3 (E2F3) and induce 
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apoptosis in neuroblastoma (Welch et al., 2007). In chronic lymphocytic leukemia, miR-15a 
and miR-16-1 are deleted or downregulated, however over-expression of these miRNAs in 
leukemic cell line model negatively regulated the expression of anti-apoptotic BCL2 protein 
(Cimmino et al., 2005). 
 
Figure 5: MicroRNA as oncogenes and tumor suppressors 
Depending on the cellular context, miRNAs could function either as oncomiRs or 
tumor-suppressors. For instance, the polycistronic miR-17-92 cluster (includes miR-17-3p, miR-
17-5p, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92a-1) located at the genomic locus 
13q31, was not only over-expressed in tumor-cell lines but also amplified in tumors in diffuse 
large B-cell lymphoma. In addition, in vivo studies of miR-17-92 over-expression in transgenic 
mouse model of human B-cell lymphoma resulted in aggressive tumors, indicating the 
oncogenic role of miR-17-92 miRNA in cancer progression (Ota et al., 2004, He et al., 2005). 
However, in another study, the c-Myc induced miR-17-92 cluster targeted and decreased the 
expression of the E2F1, involved in transition of G1-S phase of cell cycle progression, 
suggesting a tumor suppressor activity of this miRNA cluster (O'Donnell et al., 2005). 
MiRNAs can function in complex regulatory circuits and feedback mechanisms. They 
are shown to work together in groups and co-operate to regulate oncogenes necessary for tumor 





were silenced, which led to the over-expression of c-Myc and its targets involved in 
proliferation and survival. Interestingly, over-expression of c-Myc led to repression of some c-
Myc targeting miRNAs, indicating a feedback mechanism in regulation of c-Myc expression 
(Bueno et al., 2011). 
Table 3: Key microRNAs with oncogenic and tumor suppressor roles in neuroblastoma 
miRNA Regulation mRNA targets Function Reference 
miR-17-92 Up-regulated DKK3 Oncogenic (De Brouwer et al., 2012) 
miR-34a Down-regulated MAP3K9 Tumor suppressive (Tivnan et al., 2011) 
miR-21 Up-regulated PTEN Oncogenic (Chen et al., 2012) 
miR-376c Down-regulated CCND1 Tumor suppressive (Bhavsar et al., 2018) 
miR-380 Up-regulated TP53 Oncogenic (Swarbrick et al., 2010) 
miR-193b Down-regulated MCL1,CCND1,MYCN Tumor suppressive (Roth et al., 2018) 
miR-15a Up-regulated RECK Oncogenic (Xin et al., 2013) 
miR-323a Down-regulated STAT3 Tumor suppressive Manuscript I 
 
The expression and function of oncomiRs can be increased or upregulated by multiple 
mechanisms including genomic amplifications, activating mutations, transcriptional activation 
and loss of epigenetic silencing. In contrast, loss of tumor-suppressor miRNAs can be due to 
genetic deletions, in-activating mutations, transcriptional repression and epigenetic silencing 
mechanisms (Lujambio and Lowe, 2012). Overall, the regulation of miRNA expression in 
cancer is very complex and therefore the mechanisms pertaining to the deregulation of miRNAs 
are discussed in the next section. 
Mechanisms of microRNA deregulation in cancer 
The deregulation or differential expression of miRNAs in cancer is undisputed. Not a 
single universal mechanism but a combination of several different mechanisms operate to 
modulate the expression profiles of individual or group of miRNAs in cancer setting (Deng et 
al., 2008). The mechanisms of miRNA deregulation can be broadly categorized into structural 
genetic variations, epigenetic modifications, transcriptional deregulation and defects in the 
miRNA biogenesis machinery (Figure 6) (Lin and Gregory, 2015, Deng et al., 2008).  
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The structural genetic variations include the DNA-copy number alterations 
(amplifications, deletions, and translocations) which are implicated in modulating the 
expression of miRNAs in cancers (Lujambio and Lowe, 2012, Deng et al., 2008). For instance, 
in chronic lymphocytic leukemia frequent deletions of chromosomal region 13q14 harboring 
the miRNAs miR-15 and miR-16 were observed in more than 50% of patients (Calin et al., 
2002). In another study, an amplification of C13orf25 locus at 13q31-32 containing seven 
miRNA polycistronic cluster was reported in lymphoma patients (Ota et al., 2004, Tagawa and 
Seto, 2005).  
In addition to genomic alterations, transcriptional regulators also play an important role 
in modulating the expression of miRNAs in cancer. For example, the activation of tumor 
suppressor gene, tumor protein P53 (TP53) led to the significant upregulation of 34-miRNAs 
and downregulation of 16-miRNAs in a genome-wide screen for TP53-regulated miRNAs in 
cancer. Among the deregulated miRNAs, miR-34 showed a marked upregulation, which is a 
well-known tumor suppressor shown to target genes, involved in promoting cell growth and 
proliferation. In the same study, other miRNAs like tumor suppressive, let-7a targeting the 
oncogenes rat sarcoma (RAS), high mobility group AT-Hook 2 (HMGA2) and miR-15a/16 
targeting the BCL-2 were also identified (Tarasov et al., 2007).  In another example, the 
transcriptional factor encoded by the proto-oncogene c-Myc, directly activates the expression 
of oncogenic miR-17-92 cluster (O'Donnell et al., 2005). Interestingly, c-Myc has been shown 
to repress a broader set of miRNA expression in mouse models of B cell lymphoma (Chang et 
al., 2008). 
Defects in the miRNA biogenesis machinery can also affect the miRNA expression. In 
the first step of miRNA biogenesis, RNA polymerase II transcribes pri-miRNAs from miRNA 
genes (Lee et al., 2004), which has been shown to be deregulated in several cancers. As 
mentioned earlier, different genetic abnormalities like deletions, amplifications, and 







Figure 6: The mechanisms of microRNA deregulation  
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In the second step of miRNA processing pathway, microprocessor complex, which 
contains DROSHA and DGCR8 enzymes, cleaves the pri-miRNA to generate pre-miRNA 
(Gregory et al., 2004, Denli et al., 2004). The microprocessor components DROSHA and 
DGCR8 are often dysregulated in cancer. For instance, a study by Lin and colleagues identified 
the downregulation of DROSHA in advanced stage neuroblastoma tumors, which correlated 
with the global downregulation of the miRNAs and poor clinical outcome (Lin et al., 2010). 
However, in cervical squamous cell carcinoma, the upregulation of DROSHA was observed to 
link with altered miRNA expression (Muralidhar et al., 2011). In the third step, the pre-miRNAs 
are exported to cytoplasm by XPO5 via RAN-GTP (Yi et al., 2003). A study by Melo and 
colleagues demonstrated that, an inactivating mutation in XPO5 results in trapping of pre-
miRNAs in the nucleus, impairing miRNA biogenesis machinery (Melo et al., 2010).  Defects 
have also been observed in DICER and its essential co-factor TRBP, which are responsible for 
further processing of pre-miRNAs into ~22 nucleotides mature miRNAs (Chendrimada et al., 
2005). For instance, DICER1 was shown downregulated in neuroblastoma and it correlated 
with global downregulation of miRNAs and poor clinical outcome (Lin et al., 2010). However, 
DICER was upregulated in metastatic prostate adenocarcinoma with global upregulation of 
miRNA expression and correlated with the increase in clinical stages (Chiosea et al., 2006). 
Frameshift mutations were identified in TRBP2, which caused decreased protein expression in 
sporadic and hereditary colorectal carcinomas (Melo et al., 2009). 
Epigenetic modifications like DNA methylations (mostly occurs in CpG sequences) and 
histone covalent modifications (acetylation, methylation and phosphorylation) alter the 
chromatin structure and regulate the pattern of gene expression (Portela and Esteller, 2010). 
Weber and colleagues thoroughly analyzed miRNA genes and demonstrated that 50% of 
miRNA genes are associated with CpG islands (short DNA sequences located at the gene 
promoter). Moreover, the frequency of miRNA gene promotor methylation was higher as 
compared to protein coding genes (Weber et al., 2007). Studies have reported that CpG islands 
associated with miRNA gene promoter are frequently hypermethylated in cancer leading to 
epigenetic silencing of tumor suppressor miRNAs. These miRNAs can be re-activated by the 
treatment of chromatin-modifying drugs such as inhibitors of DNA methylation and/or histone 
deacetylase (Lujambio et al., 2008). For example, miR-127, which targets the proto-oncogene 
BCL6, is hypermethylated in human cancer cells. Upon treatment with chromatin modifying 
agents, a strong upregulation of miR-127 was observed (Saito et al., 2006). In another study, 
Parodi et al., (2016) analyzed the methylation status of a set of miRNAs in neuroblastoma cell 
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lines and identified a subset of hypermethylated and downregulated miRNAs (miR-34 and miR-
124) whose targets have important roles in fundamental cell processes like growth and 
apoptosis (Parodi et al., 2016). Similar to DNA hypermethylation, DNA hypomethylation have 
been shown to upregulate the expression of oncogenic miRNAs. The let-7a-3 gene was 
hypomethylated in lung adenocarcinomas, leading to high expression of let-7a-3 having 
oncogenic functions (Brueckner et al., 2007). In addition to DNA methylation, histone 
modifications could also modulate the miRNA expression profiles in cancer (Guil and Esteller, 
2009). 
MicroRNAs and drug resistance in human cancer 
The role of miRNAs in mediating drug resistance in neuroblastoma is poorly 
understood. Very few studies have reported the direct involvement of miRNAs in modulating 
the drug resistance mechanisms in neuroblastoma (Table 4). 
In one of our miRNA profiling studies, we employed deep sequencing technique to 
identify 34-downregulated and 8-upregulated miRNAs differentially expressed in 
neuroblastoma cell lines isolated from six patients at diagnosis and at relapse following 
intensive treatments (Roth et al., 2016). In another study, Ayers and colleagues identified 
differential expression of miRNAs in chemoresistant cell line models (SH-SY5Y and UKF-
NB-3) of neuroblastoma (Ayers et al., 2015). 
Chen and collaborators found miR-21 as the first miRNA associated with drug resistance 
in neuroblastoma. They observed the increased expression of miR-21 in cisplatin-resistant SH-
SY5Y and BE(2)-M17 neuroblastoma cells as compared to parental cells. Therefore, by using 
antagomir against miR-21, they knocked down the expression of miR-21, which sensitized the 
cisplatin-resistant cells. Further, they ectopically expressed pre-miR-21 in parental cells, which 
led to increased resistance to cisplatin treatment and enhanced proliferation by modulating the 
phosphatase and tensin homolog (PTEN) protein levels (Chen et al., 2012). 
In another study, miR-204 was shown to increase sensitivity of neuroblastoma cell lines 
to cisplatin and etoposide. Surprisingly, miR-204 had no effect on neuroblastoma cell growth 
in the absence of chemotherapeutic agents. The miR-204 has been shown to directly target the 
3’UTR sequence of BCL2 and an oncogene, neurotrophic receptor tyrosine kinase 2 (NTRK2) 
both of which are important mediators in facilitating resistance to several chemotherapeutic 
agents. Moreover, BCL2 and NTRK2 are significantly associated with poor patient survival in 
chemo-resistant neuroblastoma (Ryan et al., 2012). 
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Table 4: MiRNAs involved in modulating drug resistance in neuroblastoma 
microRNA Drug/s Target/s Reference 
miR-17-5p-92 Not determined p21 and BIM (Fontana et al., 2008) 
miR-21 Cisplatin PTEN (Chen et al., 2012) 
miR-204 Cisplatin, Etoposide BCL2 and NTRK2 (Ryan et al., 2012) 
miR-137 Doxorubicin CAR (Takwi et al., 2014) 
miR-520f Cisplatin, Etoposide NAIP (Harvey et al., 2015) 
miR-155 Cisplatin TERF1 (Challagundla et al., 2015) 
miR-497 Not determined CHEK1, AKT and VEGFA (Soriano et al., 2016) 
miR-141 Cisplatin FUS (Wang et al., 2016) 
miR-137 Doxorubicin CAR (Zhao et al., 2017) 
 
Two independent reports highlighted the importance of miR-137 in modulating the 
doxorubicin sensitivity of neuroblastoma cells. Takwi and colleagues observed downregulated 
expression of miR-137 and an inverse high expression of constitutive androstane receptor 
(CAR) and MDR1 in doxorubicin-resistant neuroblastoma cells as compared to parental cells. 
Furthermore, miR-137 was shown to directly target CAR and that over-expression of miR-137 
led to sensitization of resistant cells to doxorubicin and reduction of the resistant tumor growth 
in vivo (Takwi et al., 2014). Zhao et al., (2017) proposed yet another mechanism to increase the 
sensitivity of neuroblastoma cells to doxorubicin. In this study, short-interfering RNA (siRNA) 
knockdown of histone deacetylase 8 (HDAC8) which is often upregulated and correlated with 
advance stage disease, increased sensitivity of neuroblastoma cells to doxorubicin via 
upregulation of miR-137 and inhibition of the MDR1 (Zhao et al., 2017). 
Tumor microenvironment has been shown to play important role in mediating drug 
resistance in cancers via release of exosomic miRNAs.  The study was carried out to show how 
exchange of exosomic miRNAs (miR-21 and miR-155) takes place between neuroblastoma cells 
and neighboring human monocytes and how these exchanged miRNAs affect drug resistance 
(Challagundla et al., 2015). 
31 
 
Harvey and colleagues showed that the expression of miR-520f was significantly 
reduced in post-chemotherapy tumors as compared to matched pre-chemotherapy samples. In 
the same study, a cisplatin and etoposide resistant SK-N-AS cell line was developed which 
acquired resistance via increase in expression of neural apoptosis inhibitor protein (NAIP) and 
the downregulation of miR-520f targeting 3’UTR of NAIP (Harvey et al., 2015). 
In another study, the over-expression of miR-497 reduced proliferation of multiple 
chemo-resistant neuroblastoma cell lines and induced apoptosis in MYCN-amplified cell lines. 
In addition, increased miR-497 expression also reduced tumor growth and inhibited vascular 
permeabilization in preclinical neuroblastoma mouse model. Moreover, low miR-497 
expression correlated with poor patient outcome in a cohort of human neuroblastoma samples 
(Soriano et al., 2016). 
Recently, Wang and colleagues, found that miR-141 was downregulated in both MYCN-
amplified and non-amplified neuroblastoma cell lines. Over-expression of miR-141 inhibited 
proliferation, migration and increased cisplatin chemo-sensitivity in neuroblastoma cells by 
targeting fused in sarcoma (FUS) (Wang et al., 2016). 
MicroRNA as therapeutics 
Since the discovery of miRNAs in 1993, there have been significant advances in 
deciphering the molecular mechanisms of cancer progression. Mounting studies have 
documented the prominent role of miRNAs as the post-transcriptional regulators of 
developmental and cellular processes (Croce and Calin, 2005). Indeed, they are shown to 
function as oncogenes or tumor suppressors which make them promising targets for the 
development of cancer therapeutics (Babashah and Soleimani, 2011). The most important 
advantage of miRNA is that, single miRNAs can target multiple mRNAs, affecting different 
oncogenic or tumor suppressive pathways (Croce and Calin, 2005). Moreover, miRNAs are 
shown to differentially express not only across normal and cancerous tissues but also across 
parental and drug resistant cells (Roth et al., 2016). Thus effective modulation of cancer 
associated-miRNAs could be an interesting approach in the treatment of cancer.  
Broadly, there are two main strategies to modulate the expression of miRNAs in cancer. 
Direct strategy involves the use of either the chemically-modified synthetic ds oligonucleotides 
(called mimics) or the viral based vector-constructs to re-express tumor suppressive miRNAs; 
and/or chemically-modified single-stranded (ss) anti-miR oligonucleotides (called antagomirs) 
to inhibit oncogenic miRNAs in cancer. Indirect strategy employs drugs to target the 
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components of miRNA biogenesis machinery or the epigenetic machinery, thus modulating 
miRNA expression profile in cancerous cells (Iorio and Croce, 2012, Thorsen et al., 2012).  
The stability and effective delivery of miRNAs into the target tissues are the challenges 
mainly faced in the miRNA-based therapy. Hence, scientists have come up with different 
designs and formulations for the efficient and robust delivery of miRNAs in vivo (Thorsen et 
al., 2012).  
For the success of miRNA-based therapy, efficient and safe delivery of miRNA mimics 
or antagomirs in vivo is essential. MiRNA mimics or antagomirs can be administered via 
intranasal, local and systemic routes through viruses (adeno associated viruses, AAVs or 
lentivirus constructs), lipids (neutral lipid emulsion, polyethyleneimine, atelocollagen), 
nanoparticles (iNOPs) or antimiR oligonucleotides (AMOs) (Iorio and Croce, 2012).   
Table 5: List of microRNAs with therapeutic potential in human cancers 
Micro-
RNA 


































Neuroblastoma (Fontana et 
al., 2008) 











Lung cancer (Trang et 
al., 2011) 













Several types of chemical modifications are done in order to confer nuclear resistance, 
enhance binding affinity and facilitate cellular uptake of antagomirs so that relevant miRNAs 
are exactly targeted. These antimiR chemistries of antagomirs include the use of high-affinity 
2' sugar modifications such as locked nucleic acid (LNA), 2'-O-methyl (2'-O-Me); 2'-O-
methoxyethyl (2'-MOE) and 2'-fluoro (2'-F) as reviewed by Eva van Rooij  (van Rooij and 
Olson, 2012).  
MRX34 is the first miRNA mimic to enter phase I clinical trial (ClinicalTrials.gov 
Identifier: NCT01829971) in cancer. This ds synthetic miRNA mimic is delivered by liposome 
technology. The tumor suppressor miRNA, miR-34 (MRX34) has been shown to target 24 
known oncogenes having role in diverse cell processes including survival, proliferation, 
metastasis, cell cycle and chemoresistance (Bouchie, 2013). Miravirsen (from Santris Pharma), 
an antagomir targeting miR-122 is another therapeutic microRNA to enter clinical trial for the 
treatment of hepatitis C virus (HCV). In addition, the follow up phase IIa clinical trial study 
(ClinicalTrials.gov Identifier: NCT01200420) reported miravirsen to be safe, well tolerated and 
provided prolonged antiviral activity without evidence of viral resistance (Janssen et al., 2013). 
Recently, phase II clinical trial of a synthetic miR-29 miRNA mimic, MRG-201 
(ClinicalTrials.gov Identifier: NCT02603224) from miRagen therapeutics was initiated for the 
treatment of patients with fibrotic diseases (Rupaimoole and Slack, 2017) (Retrieved from: 
http://www.miragen.com/press-release/miragen-therapeutics-announces-initiation-phase-2-
clinical-trial-mrg-201/) 
All the above strategies mentioned take into account the modulation of single miRNA 
or single miRNA family. However, the cancer phenotype may be as a result of aberrant 
expression of multiple miRNAs in co-ordination with various mRNA targets. Therefore, an 
indirect approach which employs drugs to target the epigenetic machinery is considered. 
Epigenetic modifications like methylation and acetylation of genomic DNA affects global 
miRNA expression levels. Thus, epigenetic drugs or modifiers like DNA methyltransferase 
(DNMT) inhibitors and histone deacetylase (HDAC) inhibitors which modulate the methylation 
and acetylation status, respectively, are used to revert the aberrant miRNA expression levels 
with corresponding change in relevant genes. In other words, epigenetic treatment can be used 
for the induction of specific miRNAs to serve as novel anticancer therapy (Monroig and Calin, 
2013). For example, the miR-127 which is located within a CpG island and silenced in human 
cancer cells was upregulated by the treatment of 5-aza-2'-deoxycytidine (inhibits DNA 
methylation) and 4-phenylbutyric acid (inhibits histone deacetylase). In addition, this 
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upregulation of miR-127 lead to corresponding downregulation of its potential target, BCL6, in 
human cancer cells (Saito et al., 2006). 
Yet another alternative to chemically modified antisense oligonucleotides and 
demethylating agents is the use of competitive inhibitors called miRNA sponges. These are 
transcripts expressed from strong promoters containing multiple, tandem binding sites to a 
miRNA of interest. Therefore, miRNA sponges can be used as an antagomir to decrease the 
level of oncogenic miRNAs in the cultured cells. The miRNA sponge plasmids together with 
luciferase constructs can be used for assessing transfection efficiency (by inclusion of GFP 
reporter in sponge mRNA), validation of predicted miRNA targets and to assay miRNA loss of 
function phenotype (Ebert et al., 2007). 
Choi and colleagues developed another strategy in contrast to miRNA sponges. They 
developed target protector morpholinos (ss chemically-modified oligonucleotides) to mask the 
miRNA recognition element (MRE) or the complementary miRNA binding sites in the 3’UTR 
of the target mRNA (Choi et al., 2007).  
The CCND1 and STAT3 oncogenes in human cancer 
CCND1 
The CCND1 (cyclin D1) gene was first characterized in 1991 (Xiong et al., 1991). More 
than two decades of research have established CCND1 as an important regulator of cell cycle 
progression and cancer. It is one of the most extensively documented oncogenes in human 
cancers. Given its prominent role in cell cycle regulation, alterations in levels of CCND1 have 
had oncogenic effects. Multiple converging studies point out to CCND1 as the biomarker of 
cancer phenotype and disease progression (Musgrove et al., 2011). 
During the process of cell cycle, the regulatory catalytic subunits called “cyclins” 
(especially D-type cyclins which includes cyclin D1, D2 and D3) are produced in a periodic, 
cell cycle dependent manner. Biologically, in response to growth factors or mitogenic stimuli, 
cyclin D1 gets associated with the serine-threonine protein kinases called cyclin dependent 
kinases (CDKs) - CDK4 and CDK6. The cyclin D1-CDK4/6 complex thus phosphorylate the 
tumor suppressor retinoblastoma (RB) protein which in turn releases the RB from E2F 
transcription factors. The E2F therefore transactivate genes necessary for G1-S phase of cell 
cycle progression. Consequently, the cell cycle enters DNA replication and cell division phase 
leading to cellular proliferation (Motokura et al., 1991, Baldin et al., 1993, Bartek et al., 1996, 
Musgrove et al., 2011). Moreover, other than its catalytic function in cell cycle regulation, 
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CCND1 plays a non-catalytic role in DNA repair mechanisms. Jirawatnotai and colleagues 
reported that RAD51, a component of DNA-repair machinery, interacts directly with CCND1. 
The RAD51 is an enzyme necessary for homologous recombination process, to seal DNA 
breaks using the intact copy of the DNA sequence as templates (Jirawatnotai et al., 2011). 
Furthermore, cyclin D-CDK4 also targets genes including SMADs (Matsuura et al., 2004), 
RUNX family (Shen et al., 2006) and MEF2 (Lazaro et al., 2002) associated with proliferation, 
degradation and differentiation respectively. 
Knockdown of CCND1 and its partner CDK4 leads to inactivation of RB pathway, E2F 
transcription and thus G1-cell cycle arrest in neuroblastoma (Molenaar et al., 2008) and 
apoptosis in cutaneous melanoma (Sauter et al., 1999) and squamous carcinomas (Sauter et al., 
2002). Given the role of cyclin D/CDK4/CDK6/RB pathway members in numerous aspects of 
cellular biology, the deregulation of these proteins is therefore associated with unlimited growth 
or proliferation, hence tumorigenesis. 
Extracellular signals like growth factors or mitogenic stimuli influence transcription, 
translation, degradation and thus the abundance of cyclin D1 protein in the cell system. 
Therefore, oncogenic activation of mitogenic signaling pathways may lead to abnormal increase 
in cyclin D1 protein levels. Cyclin D1 is shown to interact with numerous proteins involved in 
cell cycle regulation, transcriptional regulation and DNA repair mechanisms. Therefore, 
deregulation of cyclin D1 will significantly affect different cellular processes directly or 
indirectly and therefore have oncogenic effects (Fu et al., 2004). 
CCND1 amplification and its subsequent over-expression is one of the most common 
genetic aberrations in human cancers. CCND1 was shown to be amplified and over-expressed 
in multiple cancers including breast cancer, lung cancer, oral squamous cell carcinoma and 
malignant melanoma (Santarius et al., 2010). In mantle cell lymphoma and multiple myeloma, 
the translocation event juxtaposes CCND1 with the immunoglobulin heavy chain locus (IGH), 
leading to CCND1 over-expression (Li et al., 1999, Pratt, 2002). In addition, mutations that 
result in deregulation of CCND1 expression have been shown in mantle cell lymphoma 
(Wiestner et al., 2007), esophageal (Benzeno et al., 2006) and endometrial (Moreno-Bueno et 
al., 2003) cancers. Furthermore, altered expression of miRNAs targeting CCND1 is another 
mechanism deregulating CCND1 in human cancers. Both miR-15a and miR-16 are deleted or 
downregulated and inversely associated with CCND1 expression in non-small cell lung cancer 
(Bandi et al., 2009) and prostate cancer (Bonci et al., 2008). 
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In case of neuroblastoma, genetic aberrations and over-expression of CCND1 is 
observed, similar to other cancers. Amplification of CCND1, CDK4 and mutation of CDK6 
have been shown in a subset of neuroblastoma cell lines and tumors (Molenaar et al., 2008). In 
addition, a rearrangement in the 3’UTR sequence of CCND1 has also been shown in 
neuroblastoma tumor (Molenaar et al., 2003). Taken together, these findings suggest a crucial 
role of cyclins and CDKs in promoting cellular proliferation in neuroblastoma and demonstrate 
their potential for therapeutic intervention. 
STAT3 
The STAT3 gene was first described as a DNA binding protein activated in response to 
growth factors and having a dual function of signal transduction and activation of transcription 
(Zhong et al., 1994). STAT3 encodes one of the seven members (STAT1, STAT2, STAT3, 
STAT4, STAT5A, STAT5B, and STAT6) of the STAT protein family (Copeland et al., 1995, 
Darnell, 1997). This protein is activated in response to binding of cytokines and growth factors 
to cellular receptors, which activates membrane-associated janus kinases (JAKs). JAK in turn 
phosphorylates STAT3 at specific residues to form homo/heterodimers and translocate to cell 
nucleus. In the nucleus, STAT3 acts as a transcription factor, which regulates the expression of 
a wide range of genes involved in survival, proliferation, invasion, metastasis, angiogenesis, 
and immunosuppression (Yu et al., 2014).  
 STAT3 has been shown to be activated by numerous activators (e.g. cytokines, growth 
factors, toll-like receptors, etc.) and therefore it has a diverse range of biological functions 
(Aggarwal et al., 2006). Hence, deregulation of STAT3 can lead to oncogenesis through various 
different mechanisms. Yu et al., (2014) have reviewed the role of JAK-STAT3 signaling 
pathway in multiple biological processes including obesity and metabolism, pre-metastatic 
niche formation, cancer stem cells, and role in inflammation-mediated cancer (Yu et al., 2014). 
STAT3 is constitutively activated in diverse human cancers and hence it functions as an 
oncogene (Levy and Lee, 2002, Aggarwal et al., 2006). In a study by Ling and Arlinghaus, 
mammary tumors were induced in mice by the 4T1 breast cancer cell line followed by effective 
knockdown of STAT3 using a lentivirus small hairpin (shRNA) delivery system. This led to 
efficient blockage of tumor formation. However, mice without shRNA for STAT3 efficiently 
formed tumors. Thus, this study concluded that constitutively activated STAT3 plays an 
important role in the induction of breast tumors by regulating the expression of c-Myc and 
Twist (Ling and Arlinghaus, 2005). Contrary to this, a tumor suppressive role of STAT3 has 
also been identified in some cancers (Zhang et al., 2016). 
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In addition, multiple studies have addressed the regulation of JAK-STAT3 signaling by 
miRNAs in different cancers. MiRNAs like miR-135a (Navarro et al., 2009), miR-26a (Yang 
et al., 2013), miR-337 (Du et al., 2012), miR-9 (Zhuang et al., 2012) and let-7 (Sugimura et al., 
2012) have shown reciprocal interactions with JAK-STAT3 signaling pathway, which have a 
crucial role in regulating oncogenesis. Recent studies from Odate et al., (2017) have 
demonstrated the specific targeting and inhibition of STAT3 by generation 2.5 antisense 
oligonucleotide, AZD9150, which decreases neuroblastoma tumorigenicity and increases 
chemosensitivity (Odate et al., 2017). Also, from our studies, we have demonstrated that miR-
323a-3p has been reduced in resistant neuroblastoma cell lines and advance stage primary 
neuroblastoma tumors. Thus, over-expression of miR-323a-3p leads to reduced cell viability, 
G1-cell cycle arrest and apoptosis by targeting STAT3 in neuroblastoma (Manuscript I). 
Given the importance of JAK-STAT3 signaling in cancer, it is one of the most promising 
targets for cancer therapy. STAT3 inhibitors are being developed. For instance, several tyrosine 
kinase inhibitors are available in clinic, which could target JAK-STAT3 signaling indirectly, 















Aims of the study 
The overall aim of this study is to identify and elucidate the functional role of 
miRNAs involved in the drug resistance mechanisms in neuroblastoma.  
The specific aims of the study are as follows: 
i) To identify miRNAs and their pathways that are involved in the underlying drug 
resistance mechanisms in neuroblastoma (Paper I) 
ii) To evaluate the functional role of downregulated 14q32 locus miRNAs, miR-376c-3p 



















Summary of papers 
Paper-I 
Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated 
before and after treatment 
Roth S.A., Knutsen E., Fiskaa T., Utnes P., Bhavsar S.P., Hald O.H., Løkke C., Mestdagh P., 
Johansen S.D., Flægstad T., & Einvik C. 
Cancer Letters (2016) 372(1):128-136 
 
Recently, microRNAs (miRNAs) have been shown to modulate drug resistance in 
multiple cancers. However, the role of miRNAs in neuroblastoma chemoresistance is limited 
and poorly understood. In this study, we set out to identify miRNAs and their pathways 
involved in mediating drug resistance in neuroblastoma. We hypothesize that differential 
expression of miRNAs among parental and resistant cells could lead to development of drug 
resistance in neuroblastoma. We used next generation deep sequencing technology to determine 
the miRNA expression profiles from matched parental cell lines (isolated at diagnosis) and 
resistant cell lines (isolated at relapse after intensive treatments) from six neuroblastoma 
patients.  
We observed a downregulation of 34 miRNAs and upregulation of 8 miRNAs in the cell 
lines isolated post-treatment. RT-qPCR technique was used to confirm and validate the 
deregulated miRNA expressions. Our results were in line with previous reports, where a general 
downregulation of miRNAs is more common than upregulation of miRNAs in cancers. 
Interestingly, 22 of the 34 downregulated miRNAs were located on chromosome 14q32 locus, 
which have earlier been reported to be downregulated in multiple human cancers. Moreover, 
we also demonstrated that the reduced expression of certain chromosome 14q32 miRNAs 
correlates with poor clinical outcome in a cohort consisting of 226 primary neuroblastomas. 
Furthermore, Ingenuity pathway analysis (IPA) of differentially expressed miRNAs revealed 
important biological pathways associated with cancer progression and drug resistance. Hence, 
in this study, we identified a unique set of miRNAs which may be involved in the development 
of drug resistance in neuroblastoma. In addition, we showed that reduced expression of certain 






Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma 
cells 
Bhavsar S.P., Løkke C., Flægstad T., & Einvik C. 
Oncology Letters (2018) 16(5):6786-6794 
In paper I, we showed that downregulation of chromosome 14q32 miRNAs is associated 
with drug resistance and poor clinical outcome in neuroblastoma. In this paper, we investigated 
the previously unknown functional role of chromosome 14q32 locus miRNA, miR-376c-3p that 
is downregulated in post-therapy neuroblastoma cell line pairs. We hypothesize that restoration 
of the downregulated miR-376c-3p could reverse the resistant phenotype caused due to reduced 
expression of miR-376c-3p. 
Therefore, we first over-expressed miR-376c-3p in multiple neuroblastoma cell lines 
and demonstrated that upregulation of miR-376c-3p results in significant reduction of cell 
growth and G1-cell cycle arrest in most of these cell lines. We then used miRNA target-
prediction software (TargetScan) to identify miR-376c-3p targets mainly related to cell cycle. 
Dual luciferase reporter assay was performed to confirm and validate miR-376c-3p target. 
Finally, RT-qPCR and western blot assays were performed to quantitate miR-376c-3p mediated 
suppression of target mRNA and protein levels, respectively.  
Interestingly, we observed cell cycle related CCND1 as one of the several genes 
predicted to target by miR-376c-3p. Luciferase reporter assay further confirmed and validated 
CCND1 as a direct target of miR-376c-3p. As expected, the mRNA and protein levels of 
CCND1 were significantly reduced in miR-376c-3p transfected cells as compared to negative 
control (NC) transfected cells. Hence, in this paper we proposed that miR-376c-3p could affect 












Hsa-miR-323a-3p targets STAT3 and induces G1-cell cycle arrest and apoptosis in 
neuroblastoma cells 
Bhavsar S.P., Olsen L., Løkke C., Flægstad T., & Einvik C. 
Manuscript 
 
Recently, the role of microRNAs (miRNAs) in modulating drug resistance in multiple 
cancers has emerged as a promising therapeutic approach in the treatment of therapy-resistant 
tumors. However, the role of miRNAs in neuroblastoma drug resistance is poorly understood.  
In our previous research, we have demonstrated that miR-323a-3p is downregulated in 
post-chemotherapy neuroblastoma cells as compared to matched pre-chemotherapy cells. 
Moreover, miR-323a-3p is downregulated in stage 4 vs stage 1-2 in a cohort of 226 primary 
neuroblastoma tumors. Therefore, in this study, we set out to investigate the functional role of 
miR-323a-3p in neuroblastoma. 
We used RT-qPCR to quantitate the basic expression of miR-323a-3p in BE(2)-C, Kelly 
and SHSY-5Y neuroblastoma cell lines. The functional role of miR-323a-3p in these cell lines 
was evaluated by alamar blue-cell viability, flow cytometry and western blot assays. Luciferase 
reporter assay, RT-qPCR and western blotting techniques were used for miR-323a-3p target 
identification and quantification in neuroblastoma cell lines. 
Over-expression of miR-323a-3p resulted in significant reduction of cell viability in 
BE(2)-C, Kelly and SHSY-5Y cell lines. By flow cytometric cell cycle analysis we found G1-
cell cycle arrest in Kelly and SHSY-5Y but not in BE(2)-C cells. By western blot analysis, we 
found that miR-323a-3p induces apoptosis in BE(2)-C, Kelly and SHSY-5Y cell lines. 
Bioinformatic miRNA target prediction software (miRDB) predicted 793 potential 
target genes for miR-323a-3p. Subsequent literature search, target analysis and luciferase 
reporter assay identified and confirmed STAT3 as a direct target of miR-323a-3p. Furthermore, 
RT-qPCR and western blot analysis revealed that the mRNA and protein levels of STAT3 were 
significantly reduced in miR-323a-3p transfected cells as compared to negative control (NC) 
transfected cells. 
Thus, the study showed that over-expression of miR-323a-3p led to significant 





Discussion (Paper I, II & III) 
Chemotherapy is the primary choice of treatment for patients with high-risk 
neuroblastoma. However, resistance to chemotherapy has emerged as an important clinical 
obstacle. These high-risk patients usually relapse after prolonged treatment and eventually die 
(Habib et al., 2012). Therefore, instead of the conventional chemotherapy approaches, 
alternative strategies need to be employed which may target specific genes to combat this lethal 
disease. Mounting studies have demonstrated the ability of miRNAs to regulate the expression 
of multiple genes affecting the growth and survival of multiple cancer types (Gurtan and Sharp, 
2013). Thus, the known functionality of miRNAs to act as oncogenes or tumor suppressors 
establish that aberrant expression of miRNAs may represent a general feature of human cancer 
and provides an opportunity for therapeutic intervention. 
In this study, by deep sequencing analysis, we observed reduced expression of miR-
376c-3p and miR-323a-3p in resistant neuroblastoma cell lines as compared to matched parental 
neuroblastoma cell lines. In addition, these miRNAs were also downregulated in a cohort 
consisting of 226 primary neuroblastoma tumors. We thus propose that downregulation of miR-
376c-3p and miR-323a-3p miRNAs may be associated with underlying resistance mechanisms 
observed in resistant neuroblastoma cell lines. Over-expression of these downregulated 
miRNAs correlated with decreased survival in neuroblastoma cells by promoting G1-cell cycle 
arrest and apoptosis. Therefore, this study has implications for understanding the functional 
roles of miRNAs in neuroblastoma tumorigenesis and drug resistance. 
MicroRNAs are differentially expressed in parental and resistant neuroblastoma cell lines 
Drug resistance is one of the most important clinical obstacles in treatment of cancer. 
Multiple factors are involved in mediating cells resistant to drugs, which are described in detail 
in the introduction section. Growing evidence have established the roles of miRNAs in 
mediating drug resistance in human cancers (Ayers et al., 2015, Chen et al., 2012). In this study, 
we have characterized the roles of certain miRNAs in drug resistant neuroblastoma.  
Generally, researchers create resistant cell lines by exposing cancer cells to high 
concentrations of drugs. These in vitro-selected resistant cell lines are then subjected for the 
analysis of underlying drug resistance mechanisms. However, this process of making cells 
resistant to drug may create a significant impact on the cellular system as a whole causing high 
expression of a myriad of genes and proteins. In short, the cell system might be restructured 
drastically due to high concentration of drugs. This scenario is far from what we can imagine 
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about resistant cancerous cells present in the tumor microenvironment in the body. Owing to 
the numerous possibilities or complexities offered by the tumor microenvironment as described 
in the introduction section and the drugs pharmacokinetic and pharmacodynamic properties. It 
is very difficult to correlate the results obtained from such resistant cell lines with the naturally 
acquired resistance of the cancerous cells present in the patient’s body. Therefore, we opt for 
another strategy, which included cells isolated from neuroblastoma patients at diagnosis and 
from the same patients at relapse following chemotherapy. This strategy provided us with the 
parental cells at diagnosis which were not treated with any kind of drugs and we also got the 
resistant cells from the same patient at relapse which were treated with chemotherapeutic drugs. 
Therefore, these resistant cells obtained via naturally acquired resistance in the body at relapse 
would mimic the underlying drug resistance mechanisms more closely than the cells, which are 
created by exposure to high concentrations of drugs.   
Very few studies have demonstrated the deregulation of miRNAs and their association 
with neuroblastoma pathogenesis and drug resistance. Bray et al., (2009) have shown the 
dysregulation of miRNAs in neuroblastoma tumors caused by large-scale chromosomal 
imbalances and the over-expression of MYCN. In addition, this study concluded that patterns 
of miRNA expression might be predictive of clinical outcome (Bray et al., 2009). In another 
study by Chen and Stallings, expression profiling of 157 miRNA loci in 35 primary 
neuroblastoma tumors resulted in differential expression of 32 loci in favorable and unfavorable 
tumor subtypes. Interestingly, several miRNAs were downregulated in tumors with MYCN 
amplification. They further assessed the functional role of single locus (miR-184), and found 
that miR-184 had significant role in apoptosis. Therefore, this study concludes that differential 
patterns of miRNA expression are correlated with clinical and biological factors (Chen and 
Stallings, 2007). Similarly, Schulte and colleagues, used next-generation sequencing 
technology to analyze five favorable and five unfavorable neuroblastoma tumor samples. This 
study also revealed the differential pattern of miRNA expression in favorable versus 
unfavorable neuroblastoma (Schulte et al., 2010). Taken together all these studies, points 
towards the clinical and functional relevance of differentially expressed miRNAs in the 

















Figure 7. Schematic representation summarizing the workflow of the study. Total RNA extracted from 
neuroblastoma cell lines at diagnosis and after chemotherapeutic treatments at relapse are reverse-transcribed to 
produce microRNA-cDNA-libraries, which are further subjected to next generation sequencing. The data obtained 
after sequencing is systematically analyzed to study the functional role of miRNAs in neuroblastoma pathogenesis 
and drug resistance.  
Isolation of total RNA from neuroblastoma cell line 
pairs (at diagnosis/relapse) 
Analysis of sequencing data 
               Differential expression of 42 microRNAs 
Functional in vitro studies of selected microRNAs  
(miR-376c-3p and miR-323a-3p) 
    Next Generation Sequencing of microRNAs 
               Preparation of microRNA library  
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The roles of miRNAs in mediating drug resistance is poorly understood. Few studies 
have reported the involvement of miRNAs in mediating drug resistance in neuroblastoma. 
These studies have employed cell lines, which were created by exposing them to high 
concentration of drugs (Chen et al., 2012, Ayers et al., 2015). We therefore hypothesize that 
miRNAs may be differentially expressed across parental and naturally acquired resistant cells 
and that functional analyzes of these aberrantly miRNAs could be important in understanding 
the drug resistance mechanisms in neuroblastoma. 
Table 6. The neuroblastoma cell line pairs used in the study. 
Cell lines isolated  
at diagnosis 
Cell lines isolated  
at relapse 
Chemotherapy 
given to the patients 
CHLA-15 CHLA-20 DOX ,CTX, CDDP, VM-26 
CHLA-122 CHLA-136 DOX, ETOP, autoSCT with TBI 
NBL-W NBL-WR DOX, CTX, DAU, VCR, CDDP, DTIC, ETOP 
SK-N-BE(1) SK-N-BE(2)-C DOX, CTX, VCR, RAD 
SMS-KAN SMS-KANR DOX, CTX, RAD 
SMS-KCN SMS-KCNR DOX, CTX 
DOX: Doxorubicin; CTX: Cyclophosphamide; CDDP: Cisplatin; VM-26: Teniposide; ETOP: Etoposide; autoSCT: 
Autologous stem cell transplantation; TBI: Total body irradiation; DAU: Daunorubicin; VCR: Vincristine; DTIC: Dacarbazine; 
RAD: Local radiation. 
We used next-generation deep sequencing technology to sequence small RNA 
transcriptome from the neuroblastoma cell lines isolated from six patients at diagnosis and at 
relapse after intensive treatment regimens (Figure 7) (Table 6) (Paper I). As expected, this led 
us to identification of several hundred miRNAs differentially expressed across parental and 
resistant cell lines. Systematic analysis of the miRNA expression profiles revealed a panel of 
42 differentially expressed miRNAs, 34 of which were downregulated and eight of which were 
upregulated significantly. Interestingly, 22 out of 34 downregulated miRNAs belonged to the 
chromosome 14q32 miRNA clusters (Figure 8). The results obtained from deep sequencing 
were further confirmed and validated by RT-qPCR. The miRNA expression profiles obtained 




Figure 8. Schematic representation of the miRNA-clusters at 14q32 chromosomal region. Multiple miRNAs 
located at 14q32 chromosomal region are downregulated (bold type) and associated with poor prognosis factors 
in neuroblastoma. The miRNAs of interest, miR-376c and miR-323a are highlighted in bold and rectangular box. 
DLK1, delta like non-canonical notch ligand 1; MEG, maternally expressed; snoRNA, small nucleolar RNA; 
DIO3, iodothyronine deiodinase 3; miRNA, microRNA. 
The reduced expression of chromosome 14q32 miRNAs in tumors associated with poor 
prognosis factors was confirmed in a cohort consisting of 226 primary neuroblastomas.  
Moreover, we also applied Ingenuity Pathway Analysis (IPA), which identifies new targets, 
pathways and candidate biomarkers within the context of biological systems to gain insights 
into the nature of genes and pathways affected by the deregulated miRNAs in neuroblastoma. 
The results of this analysis revealed several biological pathways associated with cancer and 
drug resistance (Paper I).   
MiR-376c-3p and miR-323a-3p are novel microRNAs with tumor suppressive activity in 
neuroblastoma  
Since the chromosome 14q32 miRNA clusters are shown downregulated in multiple 
cancers (Zehavi et al., 2012), we focused on miRNAs from this region to study their functional 
roles in neuroblastoma. We selected miR-376c-3p and miR-323a-3p, to assess their role in the 
pathogenesis of neuroblastoma. Both miRNAs were downregulated in most of the cell lines 
isolated from patients after chemotherapeutic treatments relative to matched cell lines isolated 
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at diagnosis. In addition, the expression of miR-376c-3p and miR-323a-3p, was reduced in INSS 
stage 4 compared to stage 1-2 in a cohort of neuroblastoma tumors. Interestingly, literature 
search on miR-376c-3p and miR-323a-3p showed a dual nature of these miRNAs to act as either 
oncogenic or the tumor suppressive miRNA depending on cellular context. Taken together, all 
these important properties of miR-376c-3p and miR-323a-3p, prompted us to evaluate the 
unknown functional role of these miRNAs in neuroblastoma pathogenesis. 
The miR-376c-3p is found downregulated in multiple human cancers, including prostate 
cancer (Formosa et al., 2014), cervical cancer (Deng et al., 2016), oral squamous cell carcinoma 
(Wang et al., 2017b), intrahepatic cholangiocarcinoma (Iwaki et al., 2013), melanoma (Zehavi 
et al., 2012), osteosarcoma (Jin et al., 2013) and gliomas (Huang et al., 2017). However, it was 
upregulated in acute myeloid leukemia (Dixon-McIver et al., 2008) and gastric cancer (Shiotani 
et al., 2013). From these studies, miR-376c-3p was shown to target a set of genes including B‐
cell‐specific moloney murine leukemia virus insertion site 1 (BMI1), homeobox B7 (HOXB7), 
growth factor receptor-bound protein 2 (GRB2), transforming growth factor-alpha (TGFA), 
liver receptor homolog-1 (LRH-1), insulin growth factor 1 receptor (IGF1R) and activin 
receptor-like kinase 7 (ALK7) involved in cell growth, cell invasion (Deng et al., 2016, Wang 
et al., 2017b, Jin et al., 2013, Jiang et al., 2016), migration (Formosa et al., 2014, Wang et al., 
2017b, Iwaki et al., 2013, Zehavi et al., 2012), cell cycle arrest (Deng et al., 2016), apoptosis 
(Wang et al., 2017b) and drug resistance (Ye et al., 2011).  
We therefore performed functional studies to evaluate the effect of miR-376c-3p over-
expression on the neuroblastoma cells (Paper II). We demonstrated that over-expression of miR-
376c-3p led to suppression of cell viability and G1-cell cycle arrest in neuroblastoma cell lines. 
These results suggested that the cell cycle genes might be affected and could serve as miR-
376c-3p targets. To test this hypothesis, we used bioinformatics algorithms to predict miR-376c-
3p targets related to cell cycle regulation. TargetScan algorithm predicted CCNDl as a target of 
miR-376c-3p, which was further confirmed and validated by dual-luciferase reporter assay. Our 
experimental data showed that the expression of CCND1 mRNA and protein levels were 
significantly reduced after transfection of miR-376c-3p as compared to NC transfected cells. In 
addition, we performed a rescue experiment to see if CCND1 counteracts the effect of miR-
376c-3p induced G1-cell cycle arrest upon CCND1 over-expression. However, a modest and 
statistically insignificant effect of CCND1 over-expression on reducing the effect of miR-376c-
3p over-expression (i.e. G1-cell cycle arrest) was observed in neuroblsatoma cells. This is 
because CCND1 might be targeted not only by miR-376c-3p but also by some other miRNAs 
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simultaneously. Many studies have demonstrated that several miRNAs can target the same 
mRNA to effectively repress the target gene expression (Shukla et al., 2011). This result thus 
point out towards the role of additional miRNAs in the regulation of CCND1 expression in 
neuroblastoma cell lines. The CCND1 has been proposed as an important oncogene in a variety 
of cancers (Musgrove et al., 2011). Multiple studies have demonstrated increased expression of 
CCND1 and that knockdown of CCND1 induced G1-cell cycle arrest and inhibited Cyclin D-
Rb pathway in neuroblastoma cells (Molenaar et al., 2008, Molenaar et al., 2003, Rihani et al., 
2015). Moreover, CCND1 was also shown to be targeted by miR-34 and induce G1-cell cycle 
arrest in NSCLC (Sun et al., 2008). Taken together, our findings suggest that miR-376c-3p has 
the ability of arresting growth in neuroblastoma cells by targeting CCND1 oncogene. Further 
studies are necessitated to understand the role of additional miRNAs in the regulation of 
CCND1 in neuroblastoma. 
 A similar study was performed to evaluate the functional role of miR-323a-3p in 
neuroblastoma (Manuscript I). Previous studies have demonstrated that miR-323a-3p is 
downregulated in multiple cancers including glioblastoma (Shahar et al., 2016), osteosarcoma 
(Chen et al., 2018a), bladder cancer (Li et al., 2017) and pancreatic ductal adenocarcinoma 
(PDAC) (Wang et al., 2016) whereas upregulated in prostate cancer (Gao et al., 2015, Gao and 
Zheng, 2018). Thus, miR-323a-3p functions as both tumor suppressive or oncogenic miRNA 
by regulating growth, apoptosis, invasion and migration depending on the cellular context. 
We demonstrated that over-expression of miR-323a-3p led to suppression of cell 
viability, G1-cell cycle arrest and apoptosis in neuroblastoma cell lines. Given the tumor 
suppressive nature of this miRNA, we searched the literature for probable targets of miR-323a-
3p validated in other cancer types. RT-qPCR was performed on such selected targets. In 
addition, we used online bioinformatic tool (miRDB) to predict miR-323a-3p targets. We thus 
identified STAT3 as a target of miR-323a-3p, which was further confirmed and validated by 
dual-luciferase reporter assay. Next, we over-expressed miR-323a-3p in neuroblastoma cell 
lines and quantitated the expression of STAT3 mRNA and protein levels. Interestingly, the 
expression of STAT3 mRNA and protein levels was significantly reduced after transfection with 
miR-323a-3p as compared to NC transfected cells. Thus, we propose that miR-323a-3p 





Multiple studies have demonstrated the oncogenic role of STAT3 in diverse cancers. 
And, given the importance of JAK-STAT3 signaling in cancer, it is one of the most promising 
targets for cancer therapy (Yu et al., 2014). STAT3 inhibitors are being developed, which show 
decreased neuroblastoma tumorigenicity and increases chemosensitivity (Odate et al., 2017). 
Furthermore, several tyrosine kinase inhibitors are also developed and now available in clinic, 
which could target JAK-STAT3 signaling indirectly, ultimately leading to reduction of tumor 
growth and survival by promoting apoptosis (Yu et al., 2009). 
In a recent study, Ara et al., (2013) identified an IL-6/sIL-6R/STAT3 interactive 
pathway functioning between neuroblastoma cells and its microenvironment, which led to drug 
resistance. This study showed that STAT3 is not constitutively active in neuroblastoma cells 
and that treatment of IL-6 alone or in combination with soluble IL-6 receptor (sIL-6R) results 
in high activation of STAT3. The study demonstrated that drug-induced apoptosis of 
neuroblastoma cells was rescued with the treatment of IL-6 alone and/or in combination with 
sIL-6R. The rescue effect is observed due to the high activation of STAT3 in the cells since 
STAT3 inhibition (with STAT3 inhibitor, Stattic) was not able to protect cells from drug-
induced apoptosis (Ara et al., 2013). 
Given the important role of IL-6/sIL-6R activated STAT3 in drug resistance and our 
recent results showing that STAT3 is a direct target of miR-323a-3p in neuroblastoma. We 
hypothesize that miR-323a-3p could target STAT3 and rescue the drug-induced apoptosis in 
neuroblastoma cells. In addition, it would be interesting to find the expression of STAT3 
downstream factors such as survivin, BCL-2, etc. affected by STAT3 repression.  
To summarize, in this thesis, we were not able to address the direct role of miRNA in 
modulating drug resistance in neuroblastoma. However, we propose that miR-323a-3p could 
play a potential role in drug resistance by targeting STAT3 in neuroblastoma cells. Further 
experimental studies with chemotherapeutic drugs are necessitated to address the role of IL-
6/sIL-6R/STAT3/miR-323a pathway in modulating drug resistance in neuroblastoma.  
Lastly, our findings suggest that the reduced expression of miRNAs may contribute to 
a resistant phenotype in neuroblastoma cell lines, and therefore ectopic over-expression of these 
miRNAs should be considered for overcoming resistance. The reduced expression of multiple 
miRNAs in post-chemotherapy neuroblastoma cell lines and primary tumors indicate a strong 
functional connection between miRNAs and underlying drug resistance mechanisms in the 
worst prognostic class of neuroblastoma. In addition, our study establishes that the restoration 
of certain miRNAs could be key therapeutic goal in neuroblastoma. According to our 
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knowledge, there are very few studies demonstrating the importance of chromosome 14q32 
miRNA downregulation in neuroblastoma. Hence, additional studies are warranted to establish 
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A B S T R A C T
Neuroblastoma is a pediatric cancer of the developing sympathetic nervous system. High risk neuro-
blastoma patients typically undergo an initial remission in response to treatment, followed by recurrence
of aggressive tumors that have become refractory to further treatment. Recent works have underlined
the involvement of microRNAs (miRNAs) in neuroblastoma development and evolution of drug resistance.
In this study we have used deep sequencing technology to identify miRNAs differentially expressed
in neuroblastoma cell lines isolated from 6 patients at diagnosis and at relapse after intensive treat-
ments. This approach revealed a panel of 42 differentially expressed miRNAs, 8 of which were upregulated
and 34 were downregulated. Most strikingly, the 14q32 miRNA clusters encode 22 of the downregulated
miRNAs. Reduced expression of 14q32 miRNAs in tumors associated with poor prognosis factors was con-
firmed in a cohort consisting of 226 primary neuroblastomas. In order to gain insight into the nature of
the genes that may be affected by the differentially expressed miRNAs we utilized Ingenuity Pathway
Analysis (IPA). This analysis revealed several biological functions and canonical pathways associated with
cancer progression and drug resistance.
The results of this study contribute to the identification of miRNAs involved in the complex pro-
cesses of surviving therapeutic treatment and developing drug resistance in neuroblastoma.
© 2015 Elsevier Ireland Ltd. All rights reserved.
Introduction
Neuroblastoma is a neoplasm of the sympathetic nervous system
representing the most frequently diagnosed solid tumor in infants
[1]. As neuroblastomas originate from neuroblasts of the
sympathoadrenal lineage of the neural crest, the tumor may be
located anywhere along the sympathetic ganglia and the adrenal
medulla [2]. One hallmark of neuroblastoma is its extremely het-
erogeneous behavior ranging from spontaneous regression or
differentiation into benign histological variants to aggressive meta-
static behavior with poor prognosis in children older than 18 months
at the time of diagnosis [3,4]. Despite continued improvements in
cancer treatment, the overall survival of patients with high risk neu-
roblastoma is still only 40–50% [5].
Low risk neuroblastomas, characterized by potential spontane-
ous regression, often require no treatment or may be treated by
surgical resection. Nevertheless, even in low risk neuroblastoma,
chemotherapy cannot be avoided in all cases [6]. Irrespective of risk
factors, neuroblastomas generally respond well to initial therapy.
However, the majority of high risk patients relapse with tumors re-
fractory to standard chemotherapeutic agents [7]. Treatment failures
have been associated with acquired multidrug resistance in re-
sponse to initial therapy but also with selection and expansion of
intrinsic resistant tumor clones [7].
Beside genetic (mutation, amplification) and epigenetic changes
(DNA hypermethylation, histone-modification), recent evidence has
revealed a substantial role of microRNAs (miRNAs) in multidrug re-
sistance in various cancers [8]. MiRNAs are small (~22 nucleotides)
non-coding RNA molecules that regulate the expression of genes
at the post-transcriptional level by either direct cleavage of target
mRNAs or repression of translation [8,9]. It has been estimated that
20–30% of all human encoding genes are regulated by miRNAs. Thus,
miRNAs have been implicated to be involved in the regulation of a
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wide variety of cellular processes such as proliferation, differenti-
ation, apoptosis, and survival [9].
Whole-genome miRNA profiling revealed aberrant expression of
miRNAs in most human cancers indicating that miRNAs have crit-
ical functions in carcinogenesis and tumor progression through acting
as either oncogenes or tumor suppressors [10,11]. Furthermore, there
are increasing number of publications providing new candidate
miRNAs whose deviant expressions have been shown to influence
cellular responses to anticancer agents through modulation of sur-
vival pathways and apoptotic responses. Moreover, aberrant
expression of miRNAs targeting drug transporters and drug me-
tabolizing enzymes may also modulate drug efficiency [8].
In recent years, miRNA-based anticancer therapy has emerged
as a promising approach. The aim of miRNA-based therapy is to
restore the activity of tumor-suppressive miRNAs or to inhibit on-
cogenic miRNAs [12].
Several studies indicate that deviant expression of certain miRNAs
correlates with poor clinical outcome in neuroblastoma [13].
However, the role of miRNAs in neuroblastoma cell resistance to che-
motherapeutic drugs is limited and poorly understood.
In this study, we used next generation sequencing technology
(SOLiD ligation sequencing) to determine miRNA expression pro-
files in neuroblastoma cell lines established from patients at diagnosis
and at relapse after treatment.
Materials and methods
Neuroblastoma cell lines
We used a unique panel of twelve neuroblastoma cell lines (Table 1) isolated
from six neuroblastoma patients before (SK-N-BE(1), SMS-KAN, SMS-KCN, CHLA-
15, CHLA-122, NBL-W) and after (SK-N-BE(2), SMS-KANR, SMS-KCNR, CHLA-20, CHLA-
136, NBL-WR) treatment with combination chemotherapy regimens.
CHLA cells were grown in Iscove’s modified Dulbecco’s medium supple-
mented with 20% fetal bovine serum, 4 mM l-Glutamine and 1× ITS (5 μg/ml insulin,
5 μg/ml transferrin, 5 ng/ml selenous acid). The other cell lines were grown in RPMI-
1640 supplemented with 10% fetal bovine serum and 2 mM l-Glutamine (final
concentrations).
All cell lines were cultured at 37 °C in a humidified incubator containing a 95%
air/5% CO2 atmosphere without antibiotics. The identity of all cell lines was authen-
ticated by short tandem repeat analysis at the Center of Forensic Genetics, The Arctic
University of Norway – UiT, Norway. Cells were tested and confirmed negative for
mycoplasma contamination.
Total RNA isolation and small RNA enrichment
Total RNA was isolated from 8 × 106 cells using TRIzol (Invitrogen, Life Tech-
nologies, Carlsbad, USA), with prolonged precipitation and centrifugation steps in
order to preserve the small RNA fraction. Total RNA quantification and integrity as-
sessment were performed using Quant-iT assay (Life Technologies) and Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), respectively. All RNA used
in this study had RNA integrity number (RIN value) above 9.5. The small RNA fraction
was enriched from total RNA samples by PureLink™ miRNA Isolation Kit (Life Tech-
nologies) according to the manufacturer instructions.
Reverse transcription of miRNAs
Purity and concentration of TRIzol-isolated RNA used for real-time quantita-
tive PCR was estimated photometrically by measuring the absorbance at 260 nm
(A260) using a NanoDrop™ 1000 spectrophotometer (Thermo Scientific, Wilming-
ton, DE, USA). cDNA was synthesized from isolated total RNA using the miScript II
RT Kit (Qiagen, Crawley, UK). In short, 1 μg of isolated total RNA was brought to a
total volume of 12 μl with deionized water. 2 μl of miScript Reverse Transcriptase
Mix and 2 μl of miScript Nucleics Mix diluted in 4 μl of 5× miScript HiSpec buffer
were added to each sample. The reverse transcription was performed at 37 °C for
60 minutes followed by 95 °C for 5 minutes to terminate the reaction. The result-
ing cDNA was diluted with deionized water to achieve a concentration of 1 ng/μl.
The cDNA was stored at −20 °C.
Real-time quantitative PCR
miScript SYBR® Green PCR Kit (Qiagen) was used for quantitative real-time PCR.
The PCR was performed in a 10 μl reaction volume according to the following pro-
tocol: Each 10 μl reaction was composed of 1 μl of cDNA equivalent to 1 ng of cDNA,
2 μl of water, 5 μl of QuantiTect SYBR Green, 1 μl of 10× Universal primers and 1 μl
of 10× specific miScript primers. The following miScript Primer Assays (Qiagen) were
used: Hs_miR-337-3p_1 (MS00007651), Hs_miR-381_1 (MS00004116), Hs_miR-
375_2 (MS00031829), Hs_miR-21_2 (MS00009079).
Hs_RNU6-2_11 (MS00033740), Hs_SNORD38B_11 (MS00007490), Hs_miR-
149_1 (MS00003570) and Hs_miR-4286_1 (MS00021371) were used as internal
controls for normalization.
Amplifications were carried out according to manufacturer’s recommenda-
tions using the ABI 7300 Real-Time PCR System (Applied Biosystems, Carlsbad, CA,
USA). To confirm amplification specificity, a melt curve was generated after the com-
pletion of the amplification reaction. Expression levels of mature miRNAs were
evaluated using the ΔΔCT comparative cycle threshold method. To determine dif-
ferential expression of miRNAs between matched cell line pairs, miRNA expression
levels of cell lines isolated after therapy were calculated relative to miRNA expres-
sion levels of cell lines isolated before therapy whose mean miRNA concentration
was set to 1.
SOLiD4 next generation sequencing
Small RNA sequencing was performed according to Ref. 14 using the SOLiD4 plat-
form. In short, 100 ng of small RNA enriched samples was subjected to adaptor ligation
and subsequently cDNA synthesis. Size selected cDNAs were then barcoded, puri-
fied, and analyzed for size and concentration, before pooled into a single library that
was used in emulsion PCR. Approximately 700 million enriched beads were depos-
ited on a full glass slide for SOLiD4 sequencing.
Data analyses
The obtained raw color-space data from SOLiD4 sequencing were analyzed in
CLC Genomic Workbench (CLCbio, Aarhus, Denmark). Adaptors were trimmed, se-
quences were grouped, counted and selected according to length. Unique small RNA
sequences were mapped to the human genome (Ensembl GRCh37.74) and anno-
tated using miRBase V21. Mapping and annotation were done in color space and
only a single mismatch was allowed. Total linear count scaling was used for nor-
malization of the unique small RNA sequences, where the read numbers are given
as reads per million (RPM).
miRNA expression data from 226 primary neuroblastoma tumors were ob-
tained through the Neuroblastoma Research Consortium (NRC). Differential miRNA
expression was analyzed using a Mann–Whitney test; p-values were corrected for
multiple testing using the Benjamini–Hochberg procedure.
Ingenuity Pathway Analysis
MiRNAs with a range of at least 100 in four of the five cell line pairs and a fold
change of at least two or minus two in three of the five cell line pairs (adjusted p-val-
ue < 0.01) were analyzed with Ingenuity Pathway Analyses (IPA) (Ingenuity Systems,
Inc., Redwood City, CA, USA). Using IPA’s microRNA target filter, a list of experimen-
tally validated mRNA targets for the most significant upregulated and downregulated
miRNAs was generated. This mRNA target list was then uploaded into the ingenu-
ity knowledge base to determine affected molecular and cellular functions and the
enrichment of canonical pathways.
The p-value associated with a function or a pathway is a measure of the like-
lihood that the association between a set of focus genes (IPA Global Molecular Network
eligible molecules) in an experiment and a given process or pathway is due to random
chance. The p-values were calculated using the right-tailed Fisher’s exact test.
Table 1






Therapy given to the
patients
SMS-KAN SMS-KANR DOX, CTX, RAD
CHLA-15 CHLA-20 DOX, CTX, CDDP, VM-26
SK-N-BE (1) SK-N-BE (2) DOX, CTX, VCR, RAD
CHLA-122 CHLA-136 DOX, ETOP, autoSCT with TBI
NBL-W NBL-WR DOX, CTX, DAU, VCR, CDDP,
DTIC, ETOP
SMS-KCN SMS-KCNR DOX, CTX
Abbreviations: DOX: Doxorubicin; CTX: Cyclophosphamide; VCR: Vincristine; CDDP:
Cisplatin; ETOP: Etoposide; DAU: Daunorubicin; DTIC: Dacarbazine; VM-26:
Teniposide; RAD: local radiation; TBI: total body irradiation; autoSCT: autologous
stem cell transplantation.
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Results
Deep sequencing of miRNAs from neuroblastoma cell lines
To investigate the role of miRNAs in drug resistance in neuro-
blastoma, we used twelve neuroblastoma cell lines, consisting of
six isogenic matched pairs isolated from neuroblastoma patients at
the time of initial diagnosis and at the time of relapse following treat-
ment (Table 1).
Small RNA libraries were generated from all twelve cell lines and
subsequently sequenced by SOLiD (Sequencing by Oligonucle-
otide Ligation and Detection) on the SOLiD4 platform.
An average of 27.3 million reads were generated from the twelve
libraries, ranging from 11.5 to 45.0 million reads (Supplementary
Table S1). Raw reads were trimmed for adaptor sequence and unique
sequences reads (tags) with less than 10 read counts were dis-
carded as noise. In addition, reads with read length above 29
nucleotides were removed in order to prevent inclusion of un-
trimmed reads. This gave an average of 9.7 million reads per sample,
ranging from 5.0 to 14.0 million reads (Supplementary Table S1).
Processed sequencing reads were mapped to the human genome
as a quality control for the library preparation. Out of 116 million
reads, 81 million were mapped to either genomic or intergenomic
regions of the human genome (69.4%), and 51% of the uniquely
mapped reads corresponded to miRNAs (Fig. 1).
To determine the relationship between all small RNA profiles
across all cell lines, we performed a multivariate correlation (Pear-
son’s) analysis on the processed sequence reads and represented
the data with a correlation matrix heat map (Supplementary
Table S2). Mapping data in this fashion clearly revealed that the small
RNA expression profile from SMS-KCN correlated poorly to all other
cell lines (average r = 0.238/SD = 0.052, average between all other
cell lines r = 0.774/SD = 0.123), including the isogenic paired SMS-
KCNR cell line (r = 0.176, average between other isogenic pairs:
r = 0.843/SD = 0.152). The reason for this difference is most likely
due to selection of a substrate-adherent variant of SMS-KCN during
cultivation in our laboratory. This variant, similar to previously re-
ported SMS-KCNs cells [15], showed complete loss of N-myc protein
expression (Supplementary Fig. S1, lane 2). The loss of N-myc
expression, in this otherwise “MYCN-addicted” cell line, could explain
the extensive difference in small RNA expression. Therefore, the SMS-
KCN/SMS-KCNR pair was excluded from further analysis.
Differentially expressed miRNAs between neuroblastoma cell lines
deriving from patients before and after therapy
In order to identify differentially expressed miRNAs, unique small
RNA sequencing tags were compared between all cell lines. 157.899
unique tags were identified by at least one cell line. To avoid the
problem of high fold change values generated from low expressed
tags, only tags with a difference in expression of at least 100 RPM
(reads per million) between the highest and lowest expressed cell
lines were included. This reduced the number of unique small RNA
sequence tags to 2.449. Out of these, 908 were annotated as miRNA
sequences. However only about 1/3 of sequence tags (37.1%) were
annotated as miRNAs; this corresponded to close to 3/4 of se-
quence reads (74.2%).
Both upregulation and downregulation of miRNAs were evident
when the expression level in cell lines isolated at diagnosis was com-
pared to the corresponding matched cell line isolated after treatment.
To restrict our analysis to the most robustly expressed miRNAs, we
considered only miRNAs with a range of at least 100 in four of the
five matched cell line pairs, and a fold change of at least ± two in
three of the five cell line pairs (adjusted p-value < 0.01). Using these
strict criteria, we identified 34 downregulated and 8 upregulated
miRNAs (Table 2). Interestingly, 22 of the 34 downregulated miRNAs
are located on chromosome 14q32. However, only four miRNAs were
found to be downregulated (miR-136-3p, miR-337-3p, miR-34a-5p
and miR-381-3p) in all five neuroblastoma cell lines isolated after
therapy, three of which are located on chromosome 14q32 (miR-
136-3p, miR-337-3p and miR-381-3p).
RT-qPCR validation analysis
To independently validate the miRNA deep sequencing data, we
used RT-qPCR to examine the expression of selected miRNAs (miR-
337-3p, miR-381-3p, miR-375 and miR-21-5p) that were both
Fig. 1. Pie chart with average percentage distribution of the uniquely mapped reads. The percentage was calculated by dividing uniquely mapped read from each sub-
category by the total uniquely mapped reads from all sequence cell lines.
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up- and downregulated according to the SOLiD sequencing data. A
total of four small RNAs (RNU6 and SNORD38B), including two
miRNAs (miR-149 and miR-4286) that showed constant expression
between cell lines, were used as internal controls for normalization.
As illustrated in Table 3, the normalized expression values ob-
tained from RT-qPCR data are comparable to the sequencing data,
verifying the reliability of the SOLiD sequencing based expression
analysis.
Table 2
MiRNAs differentially expressed in neuroblastoma cell lines isolated before and after treatment.
Fold change (range)



















1.7 (177.8) 4.5 (1,321.0) 7.1 (602.6) 13.9 (430.5) −3.3 (815.5)
mir-193b-3p ↑ 16p13.12 3.8 (577.9) 1.1 (19.0) 4.7 (103.1) 2.9 (247.3) 2.7 (347.6)
mir-21-5p ↑ 17q23.1 11.7 (3,129.3) 2.0 (1,676.9) −2.8 (3,098.1) 15.8 (2,646.3) 4.2 (208.5)
mir-30a-5p ↑ 6q13 14.0 (1,347.0) 3.9 (217.6) −2.3 (50.9) −8.3 (332.4) 4.6 (128.1)
miR-375 ↑ 2q35 3.0 (181.7) 9.3 (252.8) 1.3 (5.4) −1.4 (107.2) 95.7 (204.8)
mir-424-5p ↑ Xq26.3 −4.1 (2,135.4) 2.1 (3,544.5) 33.7 (3,763.3) 2.7 (2,751.8) −1.8 (2,266.1)
mir-99b-5p ↑ 19q13.41 2.7 (31,388.9) 1.3 (4,789.8) 14.6 (11,368.3) 48.8 (28,895.5) 1.1 (2,915.4)
mir-100-5p ↓ 11q24.1 −21.3 (1,759.8) −3.1 (3,653.3) 4.4 (167.8) 3.3 (49.5) −4.9 (391.6)
mir-10b-5p ↓ 2q31.1 −11.8 (6,303.5) −1.3 (1,696.8) −4.4 (3,597.3) −10.0 (1,952.7) 1.3 (1,801.3)
mir-136-5p ↓ 14q32.2 −5.7 (154.8) −7.3 (284.8) −70.9 (3,319.2) 2.0 (731.6) −220.4 (538.7)
mir-136-3p ↓ 14q32.2 −5.0 (131.3) −7.5 (111.6) −3.9 (469.9) −2.4 (521.6) −4.8 (67.0)
mir-138-1-5p mir-138-2-5p ↓ 3p21.32
16q13
−20.8 (2,671.1) 1.0 (52.5) −5.5 (249.3) −13.1 (2127) 1.7 (484.7)
mir-154-3p ↓ 14q32.31 −10.5 (293.3) −6.4 (236.7) 3.8 (324.0) −4.9 (370.6) −6.0 (28.1)
mir-16-2-3p ↓ 3q25.33 6.2 (1,290.3) 3.8 (289.1) −19.8 (547.3) −3.5 (781.9) −65.6 (411.7)






−68.5 (6,139.3) −25.4 (7,230.1) 8.0 (3,106.5) 3.3 (194.4) −2.3 (5,723.0)
mir-29b-1-3p mir-29b-2-3p ↓ 7q32.3
1q32.2
−2.0 (806.7) 1.7 (1,154.1) 1.2 (324.9) −2.5 (756.9) −3.1 (1,903.6)
mir-30e-5p ↓ 1p34.2 1.4 (480.3) 1.2 (230.0) −4.0 (769.2) −2.2 (1,519.2) −2.8 (694.4)
mir-323a-3p ↓ 14q32.31 −34.3 (627.4) −5.9 (440.1) −1.3 (89.2) 1.3 (339.1) −3.0 (372.9)
mir-323b-3p ↓ 14q32.31 −49.5 (713.1) −7.2 (443.6) −1.2 (54.5) −2.0 (753.1) −3.9 (88.4)
mir-329-3p ↓ 14q32.31 −12.7 (644.5) −5.6 (412.0) 1.3 (157.5) −1.5 (571.9) −6.2 (317.4)
mir-337-3p ↓ 14q32.2 −10.6 (795.1) −5.9 (783.6) −1.4 (436.0) −2.5 (1505.1) −15.1 (423.6)
mir-33a-5p ↓ 22q13.2 2.1 (199.6) 1.0 (2.2) −3.7 (216.4) −3.1 (388.7) −6.0 (117.3)
mir-34a-5p ↓ 1p36.22 −44.0 (1245.8) −5.3 (491.5) −5.3 (40.1) −4.2 (728.5) −4.5 (1684.0)
mir-369-3p ↓ 14q32.31 −7.8 (101.0) −7.7 (192.3) −1.7 (70.5) −6.2 (182.5) −4.0 (14.3)
mir-376a-3p ↓ 14q32.31 −19.9 (12,039.2) −6.9 (8,317.8) 1.3 (1,776.5) 53.6 (4,975.9) −4.0 (1,617.0)
mir-376b-3p ↓ 14q32.31 −10.3 (866.4) −5.4 (416.2) −1.2 (176.3) 211.8 (783.8) −11.7 (221.3)
mir-376c-3p ↓ 14q32.31 −13.9 (19,313.9) −4.9 (9,416.1) 2.8 (7,216.9) 57.3 (11,853.6) −2.4 (1,195.9)
mir-379-5p ↓ 14q32.31 −16.0 (385.6) −9.6 (389.7) −3.3 (975.8) −1.4 (179.5) 9.0 (33.3)
mir-380-3p ↓ 14q32.31 −8.1 (202.0) −6.0 (165.0) 3.0 (145.8) −2.3 (177.4) −5.5 (43.6)
mir-381-3p ↓ 14q32.31 −2.8 (146.0) −8.0 (149.1) −5.4 (781.9) −6.3 (729.5) −3.2 (16.4)
mir-409-3p ↓ 14q32.31 −29.3 (3,316.0) −9.6 (2,853.3) 16.8 (2,853.6) −1.6 (323.8) −32.8 (195.5)
mir-410-3p ↓ 14q32.31 −9.1 (173.0) −6.4 (109.7) 6.2 (142.1) −8.5 (232.3) −2.9 (3.4)
mir-4454-5p ↓ 4q32.2 1.0 (39.2) −2.6 (576.8) −2.4 (2,019.0) −2.1 (1,938.4) −3.8 (2,440.5)
mir-487a-3p ↓ 14q32.31 −19.5 (424.9) −5.7 (335.9) 6.9 (489.3) −3.3 (283.8) −3.7 (25.2)
mir-487b-3p ↓ 14q32.31 −13.7 (2,097.6) −7.1 (1,957.0) 2.1 (1,472.5) −1.7 (1,377.1) −3.4 (478.7)
mir-494-3p ↓ 14q32.31 −9.8 (903.2) −5.9 (715.8) 4.4 (655.8) −2.3 (310.8) −5.4 (134.0)
mir-495-3p ↓ 14q32.31 −12.4 (5,963.3) −3.6 (3,744.1) 16.5 (5,721.3) −3.5 (1,566.7) −6.5 (284.2)
mir-543-3p ↓ 14q32.31 −13.3 (819.5) −4.3 (578.7) 11.1 (589.8) −2.7 (173.1) −5.3 (29.1)
mir-654-3p ↓ 14q32.31 −6.0 (1,695.6) −469.9 (2,033.0) 6.6 (1,727.3) −1.6 (567.1) −39.0 (607.0)
mir-7-2-3p ↓ 15q26.1 −1.6 (119.7) −35.8 (393.6) −7.5 (129.1) −2.9 (219.5) 7.9 (48.8)
Considered are miRNAs with a range of at least 100 in four of the five cell line pairs and a fold change of at least minus two or two in three of the five cell line pairs (ad-
justed p-value < 0.01).
Table 3
Validation of the SOLiD sequencing data by qRT-PCR.
miRNA SMS-KAN vs. SMS-KANR CHLA-15 vs. CHLA-20 SK-N-BE1 vs. SK-N-BE2 NBL-W vs. NBL-WR CHLA-122 vs. CHLA-136
SOLiD RT-PCR SOLiD RT-PCR SOLiD RT-PCR SOLiD RT-PCR SOLiD RT-PCR
hsa-miR-381-3p 0.36 0.5547 0.12 0.3008 0.19 0.4285 0.31 0.3241 0.16 1.3104
hsa-miR-375 3.0 3.8966 9.3 2.6631 1.3 1.4702 95.7 60.1543 0.7 0.8936
hsa-miR-21-5p 11.7 3.2547 2.0 3.2340 0.3618 0.4620 4.2 1.7716 15.8 2.0768
hsa-miR-337-3p 0.0940 0.6791 0.1683 0.5139 0.6947 1.1014 0.0663 0.1987 0.4038 1.2062
Expression levels of mature miRNAs were evaluated using the ΔΔCT comparative cycle threshold method. MiRNA expression levels of cell lines isolated after treatment
were calculated relative to miRNA expression levels of cell lines isolated before therapy whose mean miRNA concentration was set to 1. RNU6, SNORD38B, miR-149 and
miR-4286 were used as housekeeping genes. Results are given as mean from three independent reverse transcription reactions and triplicate qPCR reactions.
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Reduced expression of 14q32 miRNAs correlates with poor prognosis
factors in neuroblastoma tumors
To investigate whether the expression of 14q32 miRNAs is as-
sociated with prognostic markers of poor outcome in neuroblastoma
patients, the expression levels of 14q32 miRNAs were evaluated in
a cohort of 226 primary neuroblastoma tumors with known MYCN
status and International Neuroblastoma Staging System (INSS). As
can be seen from Fig. 2, the mean expression levels of 14 of the 22
mature 14q32 miRNAs from Table 2 were lower in MYCN-amplified
(MNA) tumors compared to MYCN single-copy (MNSC) tumors.
Similarly, these miRNAs were also lower expressed in INSS stage 4
tumors compared to the tumors belonging to stage 1 and 2
(Supplementary Fig. S2).
Functional enrichment analysis on predicted miRNA targets
To analyze miRNA expression data in the context of known bi-
ological functions, a functional enrichment analysis using Ingenuity
Pathway Analysis (IPA) was performed.
Fig. 2. Reduced expression of 14q32-miRNAs in MNA neuroblastoma tumors. Box plot presentations showing relative expression levels of mature 14q32-miRNAs in MYCN-
amplified (MNA, n = 40) and MYCN single-copy (MNSC, n = 160) primary neuroblastoma tumors. The boxes represent the 25%–75% quartiles. The horizontal line in the boxes
represents the median level. Whiskers represent the non-outlier range. Open circles represent the outliers. Adjusted p-values (adj p) were calculated using the Benjamini–
Hochberg procedure.
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The 34 downregulated and 8 upregulated miRNAs were pre-
dicted to target 425 unique experimentally observed mRNAs
(Supplementary Table S3). This resulting list of mRNAs was used to
determine affected molecular and cellular functions (threshold p-val-
ue < 0.05) that are predicted to be affected by the differentially
expressed miRNAs. As expected, IPA identified several functional cat-
egories with molecular and cellular functions, like the top scoring
functions ‘Cell Death and Survival’ and ‘Cellular Growth and Pro-
liferation’, associated with chemo- and radiotherapy resistant
phenotypes (Table 4). The full list of predicted miRNA target genes
associated with the ten most affected IPA functional categories is
shown in Supplementary Table S4.
Furthermore, the predicted targets were enriched for several ca-
nonical pathways known to be involved in drug resistance, including
PI3K/AKT signaling, STAT3 signaling, G1/S checkpoint regulation, p53
signaling (Fig. 3). The complete list of putative targets related to the
ten most affected canonical pathways is shown in Supplementary
Table S5.
Discussion
Most drug resistance cell model systems for neuroblastoma, as
well as many other cancers, are based on in vitro selection of re-
sistant cell lines by continuous or intermittent exposure of cells to
a single chemotherapeutic agent [16–21]. To investigate the role of
miRNAs during drug resistance development in neuroblastoma, we
determined miRNA expression profiles by SOLiD deep-sequencing
in clinically relevant neuroblastoma models, consisting of cell lines
established from the same patients at diagnosis (pre-treatment) and
at relapse after therapy (post-treatment). In these model systems,
drug resistance was established in the patients during treatment,
and the resistance patterns have been shown to generally corre-
late with the treatment intensities and the drugs that the patients
were exposed to [22,23].
We identified a panel of miRNAs that are either downregulated
(34 miRNAs) or upregulated (8 miRNAs) in the cell lines isolated
after treatment. In concordance with previously published studies
on miRNA expression in cancer cell lines, we observed
downregulation of miRNAs to be more common than upregulation
[24]. The differential expression of a subset of these miRNAs was
validated using RT-qPCR.
Most strikingly, 22 of the 34 (65%) downregulated miRNAs are
encoded by miRNA clusters located at chromosome 14q32. This locus
harbors two miRNA clusters (14q32.31 and 14q32.2 clusters), of
which the 14q32.31 cluster is the largest miRNA cluster identified
in the human genome [25]. The two miRNA clusters encode a total
of 47 different miRNAs. Our sequencing data identify 32 (68%) dif-
ferent miRNAs from these clusters, 6 of 8 miRNAs from the 14q32.2
cluster and 26 of 39 miRNAs from the 14q32.32 cluster (Fig. 4).
miRNA expression data from a cohort consisting of 226 primary
neuroblastoma tumors confirmed the lower expression of most of
Table 4
Functional categories containing enriched molecular and cellular functions of pre-
dicted miRNA target genes differentially expressed between neuroblastoma cell lines
isolated before and after treatment.
Category p-value range Number
of targets
Cell Death and Survival 2.70 × 10−32–3.07 × 10−06 167
Cellular Growth and Proliferation 9.79 × 10−30–3.77 × 10−06 177
Cellular Development 3.88 × 10−29–3.77 × 10−06 159
Cellular Movement 3.00 × 10−27–2.54 × 10−06 121
Cell Cycle 7.51 × 10−22–3.77 × 10−06 97
Gene Expression 1.25 × 10−20–2.01 × 10−08 122
Cell Morphology 2.54 × 10−18–2.97 × 10−06 71
Cell-To-Cell Signaling and Interaction 1.31 × 10−10–2.45 × 10−06 59
DNA Replication, Recombination, and
Repair
4.52 × 10−10–3.77 × 10−06 63
Post-Translational Modification 7.68 × 10−10–1.41 × 10−07 41
The p-value range (Fisher’s exact test) indicates the p-values of the various path-
ways and processes belonging to that category. The number of targets indicates the
total number of predicted miRNA targets associated with the functional category.
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Fig. 3. Canonical pathways predicted to be affected by differential miRNA gene expression. The diagram shows the ten most significantly enriched canonical pathways iden-
tified by IPA. The x-axis displays the −log of P value, which is calculated by Fisher’s exact test.
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our identified 14q32 miRNAs in tumors exhibiting poor prognosis
factors like MNA and INSS stage 4. We also identified several ad-
ditional 14q32 miRNAs (all observed to be repressed in cell lines
isolated after treatment but not following our strict criteria) that
were lower expressed in the tumors associated with poor progno-
sis (Supplementary Fig. S3).
The 14q32.31 miRNA cluster has previously been shown to be
downregulated in multiple human cancers, including glioblas-
toma multiforme, ovarian cancer, breast invasive carcinoma, kidney
renal clear cell carcinoma, stomach adenocarcinoma, prostate ad-
enocarcinoma and bladder urothelial cancer [26]. Using genome-
wide miRNA expression profiling, Xu et al. found strong
downregulation of all miRNAs coded by the 14q32.31 cluster in
doxorubicin-resistant K562 leukemia cells when compared to their
drug-sensitive counterparts [27]. Furthermore, miR-381 and miR-
495, which also in our study were significantly downregulated in
the post-treatment cell lines, were previously shown to specifical-
ly repress expression of MDR1/p-gp through direct targeting of the
3’UTR. Similar to our results, most aberrantly expressed miRNAs were
downregulated in drug resistant cells, while miR-375 was
upregulated.
miR-337-3p, encoded by the 14q32.2 miRNA cluster, is one of the
miRNAs that was downregulated in all cell lines isolated from pa-
tients after treatment. miR-337-3p has previously been reported to
sensitize lung cancer cells to taxanes by direct targeting and re-
pression of signal transducer and activator of transcription 3 (STAT3)
and Ras-related Protein 1A (RAP1A) expression [28]. STAT3 is well
known for its positive regulation of several survival proteins in-
cluding cyclin D1, survivin, c-myc, Bcl-XL and Bcl-2 [29]. Unlike many
other cancers, STAT3 is not constitutively activated in neuroblas-
toma; however, in vitro studies demonstrate that bone marrow-
derived IL-6 increases the proliferation and decreases etoposide-
induced apoptosis through activation of STAT3 in neuroblastoma cells
[30].
Very recently, Xiang et al. showed that miR-337-3p is
downregulated in neuroblastoma tumor samples and that miR-337-
3p expression is inversely correlated with advanced neuroblastoma
stages, tumor progression and MYCN amplification [31]. Exoge-
nous overexpression of miR-337-3p inhibited growth, invasion,
metastasis and angiogenesis in neuroblastoma cell lines. miR-337-
3p was shown to directly bind the matrix metalloproteinase 14
(MMP-14) promoter to repress its transcription. These studies in-
dicate that miR-337-3p could be a critical regulator of several
processes involved in survival and progression of aggressive
neuroblastomas.
Allelic loss of the long arm of chromosome 14 (14q) has been
reported to be quite common (20–30%) in neuroblastoma patients
despite no correlation between 14q loss of heterozygosity (LOH) and
clinicopathologic features [32,33]. However, thirteen miRNAs be-
longing to the 14q32.31 cluster were significantly downregulated
in high-risk neuroblastoma tumors and two of these (miR-410 and
miR-487) were proposed as prognostic markers since they were able
to discriminate high-risk from low-risk neuroblastoma [34].
Several non-14q32 differentially expressed miRNAs from this
study have previously been associated with poor clinical outcome
in neuroblastoma and chemoresistance in various other cancers. For
instance, we found that the tumor suppressor miRNA miR-34a is
downregulated in cell lines isolated from patients after treatment.
Loss or downregulation of miR-34a has been reported in several
cancers including neuroblastoma, breast and bladder cancer [35–37].
Furthermore, miR-34a overexpression sensitizes various cancer cell
lines to a number of chemotherapeutic drugs and to radiotherapy
[37–47].
Although only few miRNAs were found to be upregulated in our
study, several of these have previously been reported to be asso-
ciated with clinical outcome in neuroblastoma.
miR-21 is an established oncomir that promotes growth, me-































































Fig. 4. Schematic overview of the DLK1-DIO3 imprinted domain located on chromosome 14q32. Green and blue represent paternally and maternally expressed genes, re-
spectively. Boxed miRNA names are listed according to the miRNA IDs and not chromosomal location. MiRNAs shown in red and black are differentially expressed, but only
miRNAs labeled in red meet our strict criteria to represent the panel of differentially expressed miRNAs. MiRNAs shown in gray were not detected. DLK1: delta-like 1 homolog
(Drosophila); MEG3: maternally expressed 3; RTL1: retrotransposon-like 1; MEG8: maternally expressed 8; MEG9: maternally expressed 9; DIO3: Type III iodothyronine
deiodinase.
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by direct targeting known tumor suppressor genes [48]. We found
miR-21 to be upregulated in all cell line pairs except SK-N-BE(1)/
(2). SK-N-BE(2) has acquired a p53 mutation that we speculate is
responsible for the major difference in several differentially ex-
pressed miRNA in this cell line compared to the other post-
treatment isolated cell lines. No previous reports have shown miR-
21 to be transcriptionally modulated by p53. Increased miR-21
expression has been linked to in vitro selected cisplatin-resistant
neuroblastoma cell lines. Treatment with antagomirs of miR-21 sen-
sitized resistant cells to cisplatin treatment [18]. Furthermore, a study
using deep sequencing of neuroblastoma tumors identified miR-
181 family members (miR-181a-5p and miR-181b-5p) to be
overexpressed in unfavorable neuroblastomas [49]. In concor-
dance with this, we observed upregulation of both miR-181a-5p and
miR-181b-5p in cell lines isolated from patients after treatment. A
recent report including in vitro and in vivo experiments revealed that
miR-181a-5p confers chemoresistance in cervical squamous cell car-
cinoma by directly targeting and decreasing PRKCD expression [50].
PRKCD is a protein kinase C isoform critical for DNA damage-
induced apoptosis and chemotherapeutic drug resistance in several
cancers, including neuroblastoma [51–53]. A search through the
public available R2 database (http://r2.amc.nl) using the two largest
neuroblastoma datasets (Kocak; n = 649 and SEQC; n = 498) showed
a highly significant correlation between low expression levels of
PRKCD and poor survival of neuroblastoma patients (Supplementary
Fig. S4).
Increased expression of miR-375 has also been associated with
neuroblastoma patients with unfavorable outcome and metastatic
dissemination [54] and miR-375 was one of ten miRNAs whose in-
creased expression was associated with advanced stage disease [55].
Recently, high miR-375 expression was also associated with tumor-
igenic undifferentiated neuroblastoma cell lines and miR-375 was
shown to target HuD, a gene involved in neuronal differentiation
[56].
In order to gain insight into biological functions and pathways
that may be affected by the miRNAs differentially expressed between
the pre- and post-treatment isolated cell line pairs, we utilized In-
genuity Pathway Analysis (IPA). Predicted targets belong to several
molecular and cellular functions well known to be implicated in drug
resistant cancer cells. The top scoring functions were ‘cell death and
survival’ and ‘cellular growth and proliferation’, both of which were
recently identified as the top scoring functions affected in several
cisplatin-resistant neuroblastoma cell lines [21]. For the canonical
pathway analysis of the predicted miRNA targets, all pathways are
known to play important functions during cancer progression and
drug resistance. The roles of cancer-associated PI3K/Akt-, PTEN-,
STAT3- and p53 pathways have recently been extensively re-
viewed [57–60]. Furthermore, the aryl hydrocarbon receptor (AHR)
was recently suggested to be an important upstream regulator of
MYCN in neuroblastoma implying the involvement of AHR signal-
ing in many aspects of neuroblastoma tumorigenesis [61]. Epithelial–
mesenchymal transition (EMT) and telomerase signaling have been
implicated as important processes during development of chemo-
resistance in neuroblastoma [21,62,63]. Functional enrichment
analysis using IPA-predicted up- and downregulated miRNA target
genes separately (separate-DE), or the strong-evidence target genes
(all-DE and separate-DE) from miRTarBase, revealed similar results
(Supplementary Table S6).
Our functional enrichment analysis of differentially expressed
miRNAs has several limitations and must be interpreted with some
caution. First, IPA is a threshold-dependent tool where a user-
preselected list of interesting genes (here the criteria-selected
differentially expressed miRNAs) is used as input data. Second, the
miRNA target gene prediction is based on predetermined data-
base knowledge and was not functionally validated by experimental
testing. Third, the functional enrichment analysis considers that each
individual gene is of equal importance, which is often not the sit-
uation in biological systems. Finally, the enrichment analysis is based
on the current state of knowledge. Since new relationships between
gene products and biological functions/pathways are expected to
be unveiled in the future, the presented results capture only a subset
of the biological processes affected in the analyzed model systems.
Our work may serve as a model on which to base future inves-
tigations on the role of miRNAs in the complex processes of surviving
therapeutic treatment and developing drug resistance in neuro-
blastoma cell lines and also in clinical patient samples. However,
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Abstract. High-risk neuroblastoma is the most aggressive form 
of cancer in children. The estimated survival of children with 
high-risk neuroblastoma is 40-50% compared with low and 
intermediate risk neuroblastoma, which is >98 and 90-95%, 
respectively. In addition, patients with high-risk neuroblas-
toma often experience relapse following intensive treatments 
with standard chemotherapeutic drugs. Therefore alternative 
strategies are required to address this problem. MicroRNAs 
(miRNAs/miRs) are small, endogenously expressed 
non-coding RNAs, which when deregulated have been 
demonstrated to serve significant roles in the tumorigenesis of 
a number of different types of cancer. Results from a previous 
deep sequencing study identified 22 downregulated miRNAs 
from the 14q32 miRNA cluster differentially expressed in 
neuroblastoma cell lines isolated from 6 patients at diagnosis 
and at relapse following intensive treatments. miR-376c-3p is 
one of the 22 miRNAs that was downregulated in the majority 
of the cell lines isolated from patients post treatment. The 
present study employed reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR) to quantify the basic 
expression of miR-376c-3p in 6 neuroblastoma cell lines. The 
functional role of miR-376c-3p in the neuroblastoma cell lines 
was evaluated by alamar blue-cell viability and propidium 
iodide‑flow cytometric assays. In addition, luciferase reporter 
assays, RT-qPCR and western blotting were performed to 
identify and quantify the targets of miR-376c-3p in neuro-
blastoma cell lines. Ectopic expression of miR-376c-3p led to 
significant inhibition of cell viability and G1‑cell cycle arrest 
in multiple neuroblastoma cell lines by reducing the expres-
sion of cyclin D1, an oncogene critical for neuroblastoma 
pathogenesis. The results of the present study provide novel 
insights into the functional role of miR-376c-3p and suggest 
new approaches for the treatment of neuroblastoma.
Introduction
Neuroblastoma is the most common childhood malignancy 
derived from the primitive cells of the sympathetic nervous 
system (1). It accounts for ~15% of all pediatric oncology 
deaths (2). The treatment of patients with advanced neuro-
blastoma or high-risk neuroblastoma is still a challenge due 
to several factors including, dose-limiting toxicity to standard 
chemotherapeutic agents, disease heterogeneity and tumor 
regression (3). Moreover, these patients have a very poor 
prognosis with the overall ten-year survival rates of less than 
10% (4). Therefore, the development of innovate alternate 
treatment strategies is necessary to increase the treatment 
effectiveness and lower toxicity.
MicroRNAs (miRNAs/miRs) are a large family of small 
(~22-25 nucleotides), endogenous, non-coding RNAs, which 
binds the partial or perfect complementary sequences in the 
3'untranslated region (3'UTR) of target messenger RNAs 
(mRNAs) leading to translational repression or mRNA degra-
dation (5). They regulate the expression of genes involved in 
proliferation, apoptosis, development and stress response. Thus, 
miRNAs have shown to play an important role in the initiation 
and progression of cancer (5). Depending on their respective 
target, miRNAs can act as oncogenes and or tumor suppres-
sors (6). miRNAs are differentially expressed across cancer 
types and microRNA‑profiling studies have revealed a general 
downregulation in tumors as compared with normal tissues (7). 
Interestingly, growing evidence have now shown the potential 
of aberrant expression of miRNAs to use as the prognostic and 
diagnostic biomarkers of human malignancies (6).
miR-376 family of miRNAs comprises of miR‑376a2, 
miR‑376b, miR‑376c (earlier known as miR‑368), miR‑376b1 
and miR‑376b2 and their sequence identity is highly similar 
to mouse miR‑376a‑c miRNAs (8). miR-376 family members 
are located on chromosome 14 in humans and at the distal 
end of mouse chromosome 12 (9). They are expressed in 
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placenta, developing embryos, and adult tissues (8). The 
expression of miR‑376c is downregulated in many human 
malignancies including cervical cancer (10), prostate 
cancer (11), oral squamous cell carcinoma (12), intrahepatic 
cholangiocarcinoma (13), melanoma (14), osteosarcoma (15) 
and gliomas (16). However, it has been shown that miR‑376c 
is upregulated and it act as oncogenic in acute myeloid 
leukemia (17) and gastric cancer (18). In addition, forced 
expression of miR‑376c enhance ovarian cancer cell survival 
by targeting activing-receptor like kinase 7 (19). Whereas, 
forced overexpression of miR‑376c suppressed growth and 
invasion of non-small cell lung cancer (20). According to our 
knowledge, there is no report regarding the role of miR‑376c in 
neuroblastoma. Thus uncovering the mechanisms of miR‑376c 
function is critical to both the fundamental understanding of 
neuroblastoma pathogenesis and novel therapeutic treatments.
The Cyclin D1 (CCND1) is one of the extensively docu-
mented oncogene in human cancers. Functionally, CCND1 
binds with cyclin-dependent kinases (CDK 4/6) which phos-
phorylate pRB family proteins, which in turn transactivates 
genes necessary for cell cycle progression (21). Dysregulated 
expression of CCND1 is a common feature in various human 
cancers (22,23). Inhibitors targeting CCND1 are thoroughly 
studied but no results have yet been proven effective (22,23). 
The CCND1 gene has one of the longest 3'UTR (~3.1 kb), 
suggesting a strong functional relevance (24). To date, many 
experimentally validated miRNAs targeting CCND1 in 
different cancers are identified. For example, let‑7e, miR‑9‑5p, 
miR‑15a‑5p, miR‑16, miR‑17, miR‑20a, miR‑106b, miR‑34a 
and miR‑206 (25-31). However, no miRNA directly targeting 
CCND1 3'UTR is yet identified in neuroblastoma.
In this study, we examined the relationship between 
miR‑376c‑3p expression and neuroblastoma tumorigenesis. 
In our previous deep sequencing study, we have analyzed 
miR‑376c‑3p expression in neuroblastoma cell lines with 
different genetic characteristics (32). miR‑376c‑3p was down-
regulated in most of the cell lines tested and therefore we 
overexpressed miR‑376c‑3p, which have had significant effects 
on cell growth and survival of neuroblastoma cells.
In addition, we demonstrated that CCND1 is a direct 
target of miR‑376c‑3p in neuroblastoma and overexpression of 
miR‑376c‑3p might have a significant influence on inhibition 
of neuroblastoma tumorigenesis.
Materials and methods
Cell culture. Human neuroblastoma cell lines, CHLA-15 and 
CHLA‑20 were cultivated in Iscove's Modified Dulbecco's 
Medium (Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany) supplemented with 20% fetal bovine serum, 4 mM 
L-Glutamine and 1X ITS (5 µg/ml insulin, 5 µg/ml trans-
ferrin, and 5 ng/ml selenous acid). CHLA-15 and CHLA-20 
were obtained from the same neuroblastoma patient prior 
to and following treatment with combination chemotherapy 
regimens, respectively. SKNAS, BE(2)-C, Kelly and SHSY-5Y 
cells were grown in RPMI-1640 medium (Sigma-Aldrich; 
Merck KGaA) supplemented with 10% fetal bovine serum 
and 2 mM L‑Glutamine (final concentrations). All cells were 
split before confluence and maintained at 37˚C in a humidified 
incubator with 4.5 to 5% CO2 atmosphere. The cell lines were 
authenticated by short tandem repeat profiling at the Center 
of Forensic Genetics, The Arctic University of Norway-UiT, 
Norway and tested negative for mycoplasma contamination. 
CHLA-15 and CHLA-20 cell lines were kindly provided by 
Children's Oncology Group, Cell Culture and Xenograft 
Repository, Texas Tech University Health Science Centre 
(Lubbock, TX, USA). BE(2)-C, SKNAS, Kelly and SHSY-5Y 
were provided by Dr. John Inge Johnsen (Childhood Cancer 
Research Unit, Department of Women's and Children's Health, 
Karolinska Institutet, Stockholm, Sweden).
Transfections. MicroRNA miR‑376c‑3p mimics or negative 
control (NC) mimics were purchased from GenePharma 
Co., Ltd. (Shanghai, China) and Ambion (Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). Transfections of 
miRNA and NC mimics (25-40 nM) were carried out using 
Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.) 
according to manufacturer's instructions.
Cell viability assay. CHLA-15, CHLA-20, BE(2)-C, Kelly 
and SHSY-5Y cells were seeded in 24-well plates and reverse 
transfected with 25 nM miR‑376c‑3p or NC mimics using 
Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.). 
Every 24 h post-transfection, alamarBlue® (Thermo Fisher 
Scientific, Inc.) cell viability assay was performed according 
to manufacturer's instructions. Ten percent of the alamarBlue 
reagent was added to the cultured cells, mixed gently and 
incubated at 37˚C for three hours. 100 µl of medium was then 
transferred to black-walled 96-well plate and fluorescence 
was monitored at 540 nm excitation wavelength and 590 nm 
emission wavelength in a microplate reader (CLARIOstar; 
BMG Labtech GmbH, Offenburg, Germany). Cell viability 
was calculated as the percentage of NC transfected cells set 
to 100 percent.
Flow cytometric analysis of cell cycle distribution. The 
BE(2)-C, Kelly and SHSY-5Y cells were seeded in 25 cm2 
culture flasks and reverse transfected with 25 nM mimics as 
described previously. 24 h post-transfection cells were tryp-
sinized and washed with 1X phosphate-buffered saline (PBS). 
The cells were then fixed in ice‑cold 70% ethanol and incu-
bated overnight at -20˚C. Next day, the ethanol fixed cells were 
centrifuged for 10 min at 0.8 x g and washed twice with 1X 
PBS and resuspended in the propidium iodide (PI) (Thermo 
Fisher Scientific, Inc.) staining solution (PBS with 100 µg/ml 
RNase, 50 µg/ml PI). The cells were then incubated for 30 min 
protected from light and stored on ice until analyzed. 
Fluorescence emitted from the PI-DNA complex was analyzed 
by flow cytometry using BD LSRFortessa™ cell analyzer (BD 
Biosciences, Franklin Lakes, NJ, USA). FlowJo 7.6.5 software 
was used to analyze the cell cycle data using the Dean-Jett-Fox 
model for cell cycle evaluation.
Bioinformatics target prediction. TargetScan (version 6.2; 
www.targetscan.org/) target prediction software was used to 
predict miR-376c-3p targets related to cell cycle.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). The Kelly, SHSY-5Y and BE(2)-C cells were seeded 
in 6-well plates and transfected with 40 nM of miR‑376c‑3p or 
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NC mimics. Cells were harvested 48 h post-transfection and 
total RNA was isolated with QIAzol®Lysis reagent (Qiagen 
Sciences, Inc., Gaithersburg, MD, USA) according to manu-
facturer's instructions and quantified by NanoDrop™ 1000 
spectrophotometer (Thermo Fisher Scientific, Inc.).
For miRNA expression analysis, complementary DNA 
(cDNA) was synthesized from isolated total RNAs using 
the miScript II RT kit (Qiagen Sciences, Inc.) according to 
manufacturer's instructions. The reaction mixture (1X) (20 µl 
reaction volume) for reverse transcription was as follows: 
Total RNA, 1 µg (diluted in RNase Free Water up to 12 µl); 
5X miScript HiSpec Buffer, 4 µl; 10X miScript Nucleics Mix, 
2 µl; miScript Reverse Transcriptase Mix, 2 µl; The cycling 
conditions were 37˚C for 60 min followed by 95˚C for 5 min. 
The cDNA obtained was diluted with 80 µl RNase Free 
Water to achieve 10 ng/µl concentration and stored at ‑20˚C 
until use. To quantitate miR‑376c‑3p levels, quantitative poly-
merase chain reaction was performed with miScript primer 
assay for miR-376c (cat. no MS00004046) using miScript 
SYBR®Green PCR kit (Qiagen Sciences, Inc.,). The miScript 
primer assay for miR-4286 (cat. no MS00021371) was used 
as an internal control for normalization. The reaction mixture 
(1X) (20 µl reaction volume) for real time PCR was as follows: 
cDNA (1 ng/5 µl), 5 µl; QuantiTect SYBR-Green PCR Master 
Mix, 10 µl; Specific miScript primer assay, 2 µl; 10X miScript 
Universal Primer, 2 µl; RNase Free Water, 1 µl.
For basic miRNA expression levels in neuroblastoma 
cell lines, the following method was used for calculations. 
Raw fluorescence values (non‑baseline corrected) gener-
ated from RT-qPCR reactions were used to calculate mean 
PCR efficiencies in the LinRegPCR software (Version 11.0; 
http://LinRegPCR.HFRC.nl.). N0 values (starting concen-
trations calculated by LinRegPCR software, N0=threshold/ 
(mean amplicon efficiencyCq)) were used to calculate the 
expression of miR‑376c‑3p relative to the stably expressed 
miR‑4286 (32). qPCR reactions were performed in trip-
licates on 2 independent biological replicates. Standard 
deviations were calculated taking into account the principle 
of error propagation (including technical and biological 
replicates).
For mRNA expression analysis, complementary DNA 
(cDNA) was synthesized from isolated total RNAs using 
the maxima reverse transcriptase (Thermo Fisher Scientific, 
Inc.) according to manufacturer's instructions. The reaction 
mixture (1X) (20 µl reaction volume) for reverse transcription 
of mRNAs was as follows: Oligo DT primer (20 µM), 1 µl; 
dNTP (10 mM each), 1 µl; Total RNA, 1 µg (diluted in RNase 
Free Water up to 13.75 µl); Incubate 65˚C for 5 min followed by 
addition of 5x RT Buffer, 4 µl; Maxima Reverse Transcriptase, 
0.25 µl; The cycling conditions were 60˚C for 30 min followed 
by 85˚C for 5 min. The cDNA obtained was diluted with 80 µl 
RNase Free Water to achieve 10 ng/µl concentration and 
stored at ‑20˚C until use. To quantitate CCND1 levels, quan-
titative polymerase chain reaction was performed with Power 
SYBR-Green PCR Master Mix (Thermo Fisher Scientific, 
Inc.). SDHA housekeeping gene was used as an internal control 
for normalization. The reaction mixture (1X) (20 µl reaction 
volume) for real time PCR was as follows: cDNA (1 ng/1 µl), 
10 µl; Power SYBR-Green PCR Master Mix, 5 µl; Forward 
Primer (10 µM), 0.4 µl; Reverse Primer (10 µM), 0.4 µl; RNase 
Free Water 4.2 µl.
Amplifications were carried out using Light Cycler 96 
SW 1.1 (Roche Diagnostics GmbH, Mannheim, Germany) and 
expression levels of miRNAs and mRNAs were evaluated using 
the comparative ΔΔCq comparative cycle threshold method (33). 
The primers used were CCND1 (forward: 5'-CCG TCC ATG 
CGG AAG ATC-3'; reverse: 5'-ATG GCC AGC GGG AAG AC-3') 
and SDHA (forward: 5'-CTG ATG AGA CAA GAT GTG GTG-3'; 
reverse: 5'-CAA TCT CCC TTC AAT GTA CTC C-3').
Western blot analysis. Cells were trypsinized and lysed in 
40 µl RIPA buffer (50 mM Tris-HCL pH 8, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented 
with 1X Protein Inhibitor Cocktail (Roche Diagnostics 
GmbH) and 1 mM dithiothreitol (DTT). Lysate was cleared 
with centrifugation (21.1 x g) and the total protein concentra-
tions were determined using DCTMProtein Assay kit (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) according to manu-
facturer's instructions. 40 µg protein was then loaded in each 
well and separated on a NuPAGE® Novex 4-12% Bis-Tris 
precast polyacrylamide gel (Thermo Fisher Scientific, Inc.). 
The separated proteins were transferred on Immobilon-FL 
PVDF membrane (EMD Millipore, Billerica, MA, USA) and 
blocked for 1 h at room temperature in 5 ml Odyssey Blocking 
Buffer (LI-COR Biosciences, Lincoln, NE, USA). The PVDF 
membrane was then incubated overnight at 4˚C with primary 
antibodies anti-Cyclin D1-(H-295)-Human Cyclin D1 Rabbit, 
polyclonal; (1:1,000; Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA) and anti-actin-(ab3280)-Human Actin Mouse, 
monoclonal (1:1,000; Abcam, Cambridge, UK). The secondary 
antibodies used were goat anti-rabbit-IRDye800CW, (1:5,000) 
(Rockland Immunochemicals, Inc., Gilbertsville, PA, USA) 
and goat anti-mouse-Alexa Fluor 680, (1:5,000; Thermo 
Fisher Scientific, Inc.). Antibody binding was detected 
using the Odyssey CLx Infrared Imaging System (LI-COR 
Biosciences). ImageJ software was used to quantify western 
blot results.
Luciferase reporter assay. The pMIR-Report-Cyclin 
D1-UTR-WT construct was a generous gif t f rom 
Dr. Laura Barkley (30) and pMIR-Report-Cyclin D1-UTR-MUT 
construct with a mutation in the putative miR‑376c‑3p seed 
sequence (mutant) was generated using QuikChange® Multi 
Site-Directed Mutagenesis kit (Agilent Technologies, Inc., 
Santa Clara, CA, USA). The primers used for mutagenesis 
were CCND1_3'UTR_miR-376c-3p (forward: 5'-CAC ATC 
TTG GCA TAC TAA TTC TTG-3'; reverse: 5'-CAA GAA TTA 
GTA TGC CAA GAT GTG-3'). To validate for mutation in seed 
sequence the mutant plasmid was sequenced using sequencing 
primer 5'-CAT CTG ATT GGA CAG GCA TG-3'. The cells 
seeded at a density of 5x104cells/well in a 12-well plate were 
co-transfected with 40 nM NC or miR‑376c‑3p mimics, 20 ng 
pRL-SV40 construct (Promega Corporation, Madison, WI, 
USA) and 100 ng wild type or mutant luciferase constructs using 
Lipofectamine® 2000 reagent (Thermo Fisher Scientific, Inc.). 
24 h post‑transfection, firefly and renilla luciferase activities 
analyzed using the Dual-Luciferase Reporter Assay (Promega 
Corporation), according to manufacturer's instructions. Firefly 
luciferase activity was normalized against renilla luciferase 
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activity and luciferase activities of miR‑376c‑3p transfected cells 
were calculated relative to NC transfected cells set to 100 %.
MicroRNA expression data from neuroblastoma tumors. 
miRNA expression data from 226 primary neuroblastoma 
tumors were obtained through the Neuroblastoma Research 
Consortium (NRC). Differential miRNA expression was 
analyzed using a Kruskal-Wallis test.
Statistical analysis. The data was expressed as mean ± standard 
deviation (SD). Unless otherwise stated, all experiments were 
performed at least three times independently. Statistical 
analysis was performed using the software GraphPad Prism 
version 5.00 for Windows (GraphPad Software, Inc., La Jolla, 
CA, USA; available at www.graphpad.com). Statistical differ-
ences between means were determined using Student's t-test. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Multiple miRNAs located at 14q32 chromosomal region are 
downregulated and their lower levels are associated with 
poor prognosis factors in neuroblastoma. Results from our 
previous study, where we used next generation sequencing 
technology (SOLiD ligation sequencing) to determine miRNA 
expression profiles in neuroblastoma cell lines established 
from patients at diagnosis and at relapse after treatment, 
identified 22 downregulated microRNAs from 14q32 miRNA 
cluster. The expression of these downregulated miRNAs was 
confirmed in a cohort consisting of 226 primary neuroblas-
tomas (32). miR‑376c‑3p, was one of the 22 miRNAs that was 
downregulated in most of the cell lines isolated from patients 
after the treatment (Fig. 1A). When miR‑376c expression 
was compared in neuroblastoma primary tumors of different 
stages from the 226-cohort, we observed a trend towards lower 
expression in advanced stage disease compared to tumors in 
stage 1 (Fig. 1B). Thus, we sought out to focus on the func-
tional role of miR‑376c‑3p in neuroblastoma.
miR‑376c‑3p reduces cell viability in neuroblastoma cell 
lines. Even though miR‑376c‑3p has been shown to play 
either the oncogenic or the tumor suppressive role in different 
cancers (10-20) the functional role of miR‑376c‑3p is not 
yet determined in neuroblastoma. Therefore, we first used 
RT-qPCR to measure miR‑376c‑3p basic expression levels 
relative to miR‑4286 in 6 neuroblastoma cell lines. miR‑4286 
was previously showed to be stably expressed in neuroblastoma 
cell lines (32). Among the cell lines, SKNAS and BE(2)-C cells 
have the highest expression level of miR‑376c‑3p, whereas 
SHSY-5Y, Kelly, CHLA-15 and CHLA-20 cells showed barely 
detectable levels of expression (Fig. 2A). In order to find out the 
potential role of miR‑376c‑3p in neuroblastoma, cell viability 
assay was performed on several neuroblastoma cell lines by 
overexpressing NC or miR‑376c‑3p mimics. The expression 
of miR‑376c‑3p was significantly increased in miR‑376c‑3p 
transfected cell lines compared with NC transfected cells, as 
validated and confirmed by RT‑qPCR (Fig. 2B). Cell viability 
alamarBlue assay was performed at 24, 48, 72 and 96 h 
post-transfection, which showed that neuroblastoma cell 
lines transfected with miR‑376c‑3p mimics, had significantly 
reduced cell viability as compared to NC transfected cells. 
Thus, ectopic expression of miR‑376c‑3p reduced the growth of 
SKNAS, CHLA-15, CHLA-20, SHSY-5Y, Kelly and BE(2)-C 
cells as compared to NC transfected cells (Fig. 2C). These 
results indicate that cell growth of neuroblastoma cell lines is 
significantly affected by overexpression of miR‑376c‑3p.
miR‑376c‑3p induces a G1‑cell cycle arrest in neuroblastoma 
cells. We did not detect significant apoptosis in miR‑376c‑3p 
transfected neuroblastoma cells using Annexin V and PARP 
cleavage assay (data not shown). Thus, we investigated the 
effects of miR‑376c‑3p overexpression on cell cycle distribu-
tion of representative neuroblastoma cell lines BE(2)-C, Kelly 
and SHSY‑5Y by flow cytometric assay. Ectopic expression 
of miR‑376c‑3p in BE(2)-C, Kelly and SHSY-5Y resulted 
in increased percentage of cells in G1-phase of cell cycle 
as compared to NC transfected cells by 13% (**P=0.0023), 
Figure 1. (A) Schematic representation of the miRNA-cluster at 14q32 chro-
mosomal region. Multiple miRNAs located at 14q32 chromosomal region 
are downregulated (bold type) and associated with poor prognosis factors 
in neuroblastoma. The miRNA of interest, miR-376c-3p is shown in bold 
and a rectangular box. (B) Box-plots of miR-376c expression in tumors from 
neuroblastoma patients at different stages. The boxes represent the 25-75% 
quartiles. The horizontal line in the boxes represents the median level. 
Whiskers represent the non-outlier range. Open circles represent the outliers. 
P=0.011, comparing the median expression level of miR376c-3p across all 
pathological stages. DLK1, Delta Like Non-canonical Notch Ligand 1; MEG, 
maternally expressed; snoRNA, small nucleolar RNAs; DIO3, iodothyronine 
deiodinase 3; miR/miRNA, microRNA.
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16% (***P=0.0001) and 9% (*P=0.0106), respectively with 
a corresponding reduction in the percentage of cells in the 
S and G2/M-phase (Fig. 3). Thus, this observation led us to 
the conclusion that decrease in cell viability might be due to 
induction of G1-cell cycle arrest in neuroblastoma cells and 
not apoptosis.
CCND1 is a direct target of miR‑376c‑3p in neuroblastoma. 
In order to investigate the underlying molecular mechanisms 
of miR‑376c‑3p induced suppression of the cell viability and 
G1-cell cycle arrest, a bioinformatics analysis was performed 
using miRNA target prediction algorithm TargetScan 
(Release 6.2; www.targetscan.org/) to predict the target genes 
of miR‑376c‑3p mainly associated with the cell cycle progres-
sion. TargetScan revealed 254 potential downstream targets 
with the conserved sites for miR‑376c‑3p (data not shown). 
It was theoretically demonstrated that miR‑376c‑3p had 
single binding site in the 3'UTR of CCND1 oncogene. Thus, 
to determine whether miR‑376c‑3p could directly target the 
predicted 3'UTR of CCND1, a dual-luciferase reporter assay 
was performed in BE(2)-C and SHSY-5Y cells. Here, we used 
a luciferase reporter containing full-length (~3.1 kb), wild 
type CCND1 3'UTR (wt) or mutant CCND1 3'UTR (MUT) 
construct having a mutation of the putative miR‑376c‑3p target 
site shown in bold and italics (Fig. 4A).
Transient co-transfection of BE(2)-C and SHSY-5Y cells 
with miR‑376c‑3p mimics and the wild type CCND1 3'UTR 
(wt) reporter construct suppressed the luciferase activity 
as compared to NC transfected cells by 35% (**P=0.0091) 
and 38% (*P=0.0135), respectively. However, the activity of 
the reporter construct mutated at the specific miR‑376c‑3p 
target site is unaffected (Fig. 4B). These data indicated that 
miR‑376c‑3p represses CCND1 expression by directly binding 
to the 3'UTR sequence of CCND1 mRNA.
miR‑376c‑3p reduces mRNA and protein levels of CCND1 in 
neuroblastoma cells. To further confirm whether miR‑376c‑3p 
directly targets CCND1 gene, neuroblastoma cells were 
transfected with miR‑376c‑3p or NC mimics and the expres-
sion levels of CCND1 was analyzed by quantitative RT-qPCR 
analysis. The levels of CCND1 mRNA was markedly 
decreased by miR‑376c‑3p overexpression in BE2-(C), Kelly 
and SHSY-5Y cells by 57% (*P=0.0110), 57% (**P=0.0017), 
and 53% (*P=0.0134), respectively as compared to NC trans-
fected cells (Fig. 5A). Moreover, we also performed western 
blot analysis and observed significant decrease in levels 
of cyclin D1 proteins upon miR‑376c‑3p overexpression in 
BE2-(C), Kelly and SHSY-5Y cells by 41% (**P=0.0089), 67% 
(**P=0.0032), and 69% (**P=0.0069), respectively as compared 
to NC transfected cells (Fig. 5B and C). Taken together, these 
results demonstrates that endogenous expression of CCND1 
gene is directly regulated by miR‑376c‑3p and suggest that 
overexpression of CCND1 gene could be reduced by enforced 
expression of miR‑376c‑3p in neuroblastoma cells.
In addition, to test whether CCND1 could also counteract 
the effect of miR‑376c‑3p induced G1 cell cycle arrest, we 
overexpressed CCND1 in SHSY-5Y cells. However, we only 
saw a modest and statistically insignificant effect of CCND1 
overexpression on reducing the effect of miR-376c-3p (Fig. 6).
Discussion
Current treatment strategies for high-risk neuroblastoma 
patients have limitations due to the refractory nature of the 
disease (2-4). Hence, alternative strategies are necessary for 
diagnosis and treatment of this disease. Mounting evidence 
have shown the potential of miRNAs as key regulators of 
Figure 2. miR-376c-3p reduces cell viability in neuroblastoma cell lines. 
(A) RT-qPCR analysis was performed to quantitate the basic expression of 
miR‑376c‑3p in 6-neuroblastoma cell lines. miR‑4286 served as an endog-
enous control for miRNAs. Error bars indicate mean ± SD of two independent 
experiments, each repeated in triplicate. (B) RT‑qPCR analysis for confirma-
tion of miR‑376c‑3p overexpression in 6-neuroblastoma cell lines transfected 
with NC or miR‑376c‑3p mimics. Expression of miR‑376c‑3p in SHSY-5Y cell 
line was set to 1 and miR‑4286 served as an endogenous control for miRNAs. 
Error bars indicate mean ± SD. of two independent experiments, each repeated 
in triplicates. (C) Cell growth analysis of neuroblastoma cells transfected 
with NC or miR‑376c‑3p mimics. BE(2)-C, Kelly and SHSY-5Y were more 
sensitive compared with SKNAS, CHLA-15 and CHLA-20. Error bars indi-
cate mean ± SD of three independent experiments repeated in triplicate. The 
results were statistically significant at 48, 72 and 96 h for all cell lines. *P<0.05. 
RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NC, 
negative control; SD, standard deviation; miR, microRNA.
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cancer pathogenesis by acting as oncogenes or tumor suppres-
sors (6). Researchers have thus exploited these properties for 
the development of the novel anticancer therapies. miRNAs 
act by inhibiting the expression of its one or more target genes. 
Hence, identification of specific miRNAs and their targets is 
very important for the diagnosis and therapy of cancer (34).
Results from our previous deep sequencing analysis study 
identified 22 downregulated microRNAs from 14q32 miRNA 
cluster differentially expressed in neuroblastoma cell lines 
isolated from six patients at diagnosis and at relapse after 
intensive treatments. miR‑376c‑3p, is one of the 22 miRNAs 
that was downregulated in most of the cell lines isolated 
from patients after treatment (32). Moreover, the expression 
of miR‑376c‑3p was reduced in International Neuroblastoma 
Staging System (INSS) stage 4 compared to stage 1-2 in a 
cohort of 226 primary neuroblastoma tumors (32). However, 
Figure 3. miR‑376c‑3p induces G1-cell cycle arrest in neuroblastoma cells. BE(2)-C, Kelly and SHSY-5Y cells were transfected with NC or miR‑376c‑3p 
mimics and the cell cycle analysis was evaluated by a propidium iodide‑flow cytometric assay. The percentage of G1‑arrested cells increased after miR‑376c‑3p 
overexpression. Error bars indicate mean ± standard deviation of three independent experiments repeated in triplicates. NC, negative control; miR, microRNA 
*P<0.05, **P<0.01 and ***P<0.001 vs. NC.
Figure 4. CCND1 is a direct target of miR‑376c‑3p in neuroblastoma. (A) The CCND1 3'UTR contain one predicted miR‑376c‑3p binding site (nucleotides 
1,792 to 1,798). In the figure, the alignment of the seed region of miR‑376c‑3p with CCND1 and the site of target mutagenesis are shown in bold and italics. 
(B) pMIR-Report-CCND1 luciferase constructs containing a full-length wt or mutated CCND1 3'UTR and miR‑376c‑3p or NC mimics, were co-transfected 
into BE(2)‑C and SHSY‑5Y cells. Luciferase activity of wt construct was significantly reduced compared with mutated constructs. Relative repression of firefly 
luciferase activity is normalized with renilla luciferase activity. Error bars indicate mean ± standard devaition of three independent experiments repeated in 
triplicates. *P<0.05, **P<0.01 vs. the adjacent NC. miR, microRNA; NC, negative control; CCND1, cyclin D1; ORF, open reading frame; UTR, untranslated 
region; wt, wild type; MUT, mutated.
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the functional role of miR‑376c‑3p in neuroblastoma is not yet 
established.
Earlier reports from various cancers have demonstrated 
the dual nature of miR‑376c‑3p to act as either the oncogenic 
or the tumor suppressive miRNA depending on the cellular 
contexts (10-20). miR‑376c‑3p is downregulated in multiple 
human cancers, including prostate cancer (11), cervical 
cancer (10), oral squamous cell carcinoma (12), intrahepatic 
cholangiocarcinoma (13), melanoma (14), osteosarcoma (15) 
and gliomas (16). In contrast, miR‑376c‑3p was upregulated 
in acute myeloid leukemia (17) and gastric cancer (18). In 
these cancers, miR‑376‑3p has been shown to target a set of 
genes including B-cell-specific moloney murine leukemia 
virus insertion site 1 (BMI1), homeobox B7 (HOXB7), 
growth factor receptor-bound protein 2 (GRB2), transforming 
growth factor-alpha (TGFA), liver receptor homolog-1 
(LRH-1), insulin growth factor 1 receptor (IGF1R) and activin 
receptor-like kinase 7 (ALK7). Other than affecting cell 
growth and proliferation, these genes act as important media-
tors of cell invasion (10,12,15, 20), migration (11-14), cell cycle 
arrest (10), apoptosis (12) and chemoresistance (19).
In order to find out how miR‑376c‑3p affects the growth 
and viability of neuroblastoma cells we first performed 
alamarBlue cell viability assay and demonstrated that tran-
sient overexpression of miR‑376c‑3p resulted in inhibition 
of cell viability in neuroblastoma cell lines. Consistent with 
this finding, we also observed that miR‑376c‑3p induced 
G1-cell cycle arrest suggesting that cell cycle genes may be 
affected and could serve as miR‑376c‑3p targets. To test this 
hypothesis, we used miRNA bioinformatics algorithms to 
predict miR‑376c‑3p targets related to the cell cycle regulation. 
TargetScan algorithm predicted the CCND1 gene as a prob-
able target of miR‑376c‑3p. CCND1 is an important cell cycle 
regulator whose mRNA contains a conserved miR‑376c‑3p 
binding site on the 3'UTR. By dual-luciferase reporter assay, 
we further demonstrated that miR‑376c‑3p could signifi-
cantly reduce luciferase activity of wild type constructs but 
not mutated CCND1 3'UTR construct confirming the direct 
regulation on CCND1 by miR‑376c‑3p. Our experimental data 
further showed that the expression of CCND1 mRNA and 
protein levels were significantly reduced after transfection with 
miR‑376c‑3p mimics as compared to NC mimics transfected 
cells. Additionally, we also performed flow cytometric rescue 
experiment by overexpression of CCND1 in neuroblastoma 
cells to see if CCND1 counteracts the effect of miR‑376c‑3p 
induced G1 cell cycle arrest. However, we only saw a modest 
and statistically insignificant effect of CCND1 overexpression 
on reducing the effect of miR‑376c‑3p overexpression.
Cyclin D1, Cyclin D2 and Cyclin D3 belongs to the class of 
cyclins, which activates the cyclin-dependent kinases (CDKs). 
These cyclins through the phosphorylation of the substrates 
at specific cell stages co-ordinates the sequential comple-
tion of DNA replication and cell division (23). Unlike other 
cyclins, CCND1 is induced by extracellular signals, including 
Figure 5. miR‑376c‑3p reduces mRNA and protein levels of CCND1 in 
neuroblastoma cells. (A) miR‑376c‑3p overexpression significantly decreases 
CCND1 mRNA levels in BE(2)-C, Kelly and SHSY-5Y. These cells were 
transfected with NC or miR‑376c‑3p mimics for 48 h and CCND1 levels 
were assessed by reverse transcription-quantitative polymerase chain reac-
tion. (B) miR‑376c‑3p overexpression significantly decreases endogenous 
levels of Cyclin D1 proteins in BE(2)-C, Kelly and SHSY-5Y. These cells 
were transfected with NC or miR‑376c‑3p mimics for 96 h and Cyclin D1 
expression assessed by western blot analysis. The β-actin antibody used as 
a loading control. (C) Quantitative analysis of Cyclin D1 protein expression 
on the western blots (n=3). Error bars indicate mean ± standard deviation of 
three independent experiments. *P<0.05 and **P<0.01 vs. the adjacent NC. 
miR, microRNA; NC, negative control; CCND1, cyclin D1.
Figure 6. CCND1 overexpression partially rescues neuroblastoma cells from 
miR‑376c‑3p induced G1 cell cycle arrest. SHSY-5Y cells were co-transfected 
with NC or miR‑376c‑3p mimics and an empty or cyclin D1 overexpression 
plasmid. 96 h after the transfection, cells were ethanol fixed and cell cycle 
analysis was evaluated by the PI‑flow cytometric assay. The results of the cell 
cycle analysis are depicted as percentage of cells in particular phases of cell 
cycle. Error bars indicate mean ± standard deviation of at least three repeats. 
miR, microRNA; NC, negative control; CCND1, cyclin D1.
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growth factor receptor activation and integrin-derived 
adhesion signaling (23,35). Functionally, CCND1 activates 
CDK4/6, which phosphorylates pRB family proteins causing 
the release of E2F transcription factors, which are essential 
for transcription of genes necessary for G1-S transition of cell 
cycle. Hence, the expression of cyclins are tightly regulated by 
variety of signaling pathways at the transcriptional as well as 
post-transcriptional levels (21).
The CCND1 gene has been proposed as an important onco-
gene in various cancers. Numerous studies have documented 
the relationship between deregulation of CCND1 and onset 
of tumorigenesis in wide variety of cancers. For instance, 
Molenaar et al (36,37) found that CCND1 levels were increased 
in neuroblastoma tumors and high expression of CCND1 led to 
tumorigenesis in neuroblastoma. In addition, Rihani et al (22) 
found that knockdown of CCND1 reduced cell proliferation, 
induced G1-cell cycle arrest and inhibited the cyclin D1-Rb 
pathway in neuroblastoma cells. Similarly, Sun and colleagues 
also found that inhibition of CCND1 and CDK6 by miR‑34a 
resulted in G1-cell cycle arrest in non-small cell lung 
cancer (38). In line with these reports, our data indicate that 
ectopic expression of miR‑376c‑3p leads to the suppression of 
endogenous CCND1 gene resulting in the reduced cell growth 
and G1-cell cycle arrest in the neuroblastoma cells.
Taken together, our study for the first time demonstrates 
that miR‑376c‑3p directly target CCND1 gene leading to 
reduced cell growth and G1-cell cycle arrest in neuroblastoma. 
Therefore, we suggest that ‘miR‑376c‑CCND1’ axis could 
be a potential molecular target for preventing neuroblastoma 
tumorigenesis.
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